<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes - Brown, J - 2017 | Cochrane Library</title> <meta content="Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes - Brown, J - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011967.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes - Brown, J - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011967.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011967.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes" name="citation_title"/> <meta content="Julie Brown" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="j.brown@auckland.ac.nz" name="citation_author_email"/> <meta content="Ruth Martis" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Brenda Hughes" name="citation_author"/> <meta content="Auckland City Hospital" name="citation_author_institution"/> <meta content="Janet Rowan" name="citation_author"/> <meta content="National Women's Health" name="citation_author_institution"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011967.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011967.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011967.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011967.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acarbose [administration &amp; dosage]; Administration, Oral; Diabetes, Gestational [*drug therapy]; Glyburide [administration &amp; dosage]; Hypoglycemia [chemically induced, prevention &amp; control]; Hypoglycemic Agents [*administration &amp; dosage, adverse effects]; Metformin [administration &amp; dosage]; Randomized Controlled Trials as Topic; Tolbutamide [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011967.pub2&amp;doi=10.1002/14651858.CD011967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011967\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011967\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","pl","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011967.pub2",title:"Oral anti\\u2010diabetic pharmacological therapies for the treatment of women with gestational diabetes",firstPublishedDate:"Jan 25, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011967.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011967.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011967.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011967.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011967.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011967.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011967.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011967.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7024 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011967.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0237"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0055"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0056"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0108"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-sec-0231"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/appendices#CD011967-sec-0242"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/table_n/CD011967StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/table_n/CD011967StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#CD011967-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Julie Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#CD011967-cr-0003">Ruth Martis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#CD011967-cr-0004">Brenda Hughes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#CD011967-cr-0005">Janet Rowan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information#CD011967-cr-0006">Caroline A Crowther</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information/en#CD011967-sec-0245">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011967.pub2">https://doi.org/10.1002/14651858.CD011967.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011967-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011967-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011967-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011967-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011967-abs-0001" lang="en"> <section id="CD011967-sec-0001"> <h3 class="title" id="CD011967-sec-0001">Background</h3> <p>Gestational diabetes mellitus (GDM) is a major public health issue with rates increasing globally. Gestational diabetes, glucose intolerance first recognised during pregnancy, usually resolves after birth and is associated with short‐ and long‐term complications for the mother and her infant. Treatment options can include oral anti‐diabetic pharmacological therapies. </p> </section> <section id="CD011967-sec-0002"> <h3 class="title" id="CD011967-sec-0002">Objectives</h3> <p>To evaluate the effects of oral anti‐diabetic pharmacological therapies for treating women with GDM. </p> </section> <section id="CD011967-sec-0003"> <h3 class="title" id="CD011967-sec-0003">Search methods</h3> <p>We searched Cochrane Pregnancy and Childbirth's Trials Register (14 May 2016), <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, <a href="http://apps.who.int/trialsearch/" target="_blank">WHO ICTRP</a> (14 May 2016) and reference lists of retrieved studies. </p> </section> <section id="CD011967-sec-0004"> <h3 class="title" id="CD011967-sec-0004">Selection criteria</h3> <p>We included published and unpublished randomised controlled trials assessing the effects of oral anti‐diabetic pharmacological therapies for treating pregnant women with GDM. We included studies comparing oral anti‐diabetic pharmacological therapies with 1) placebo/standard care, 2) another oral anti‐diabetic pharmacological therapy, 3) combined oral anti‐diabetic pharmacological therapies. Trials using insulin as the comparator were excluded as they are the subject of a separate Cochrane systematic review. </p> <p>Women with pre‐existing type 1 or type 2 diabetes were excluded.</p> </section> <section id="CD011967-sec-0005"> <h3 class="title" id="CD011967-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion and trial quality. Two review authors independently extracted data and data were checked for accuracy. </p> </section> <section id="CD011967-sec-0006"> <h3 class="title" id="CD011967-sec-0006">Main results</h3> <p>We included 11 studies (19 publications) (1487 women and their babies). Eight studies had data that could be included in meta‐analyses. Studies were conducted in Brazil, India, Israel, UK, South Africa and USA. The studies varied in diagnostic criteria and treatment targets for glycaemic control for GDM. The overall risk of bias was 'unclear' due to inadequate reporting of methodology. Using GRADE the quality of the evidence ranged from moderate to very low quality<i>.</i> Evidence was downgraded for risk of bias (reporting bias, lack of blinding), inconsistency, indirectness, imprecision and for oral anti‐diabetic therapy versus placebo for generalisability. </p> <p><b>Oral anti‐diabetic pharmacological therapies versus placebo/standard care</b> </p> <p>There was no evidence of a difference between glibenclamide and placebo groups for hypertensive disorders of pregnancy (risk ratio (RR) 1.24, 95% confidence interval (CI) 0.81 to 1.90; one study, 375 women, very low‐quality evidence), birth by caesarean section (RR 1.03, 95% CI 0.79 to 1.34; one study, 375 women, very low‐quality evidence), perineal trauma (RR 0.98, 95% CI 0.06 to 15.62; one study, 375 women, very low‐quality evidence) or induction of labour (RR 1.18, 95% CI 0.79 to 1.76; one study, 375 women; very low‐quality evidence). No data were reported for development of type 2 diabetes or other pre‐specified GRADE maternal outcomes (return to pre‐pregnancy weight, postnatal depression). For the infant, there was no evidence of a difference in the risk of being born large‐for‐gestational age (LGA) between infants whose mothers had been treated with glibenclamide and those in the placebo group (RR 0.89, 95% CI 0.51 to 1.58; one study, 375, low‐quality evidence). No data were reported for other infant primary or GRADE outcomes (perinatal mortality, death or serious morbidity composite, neurosensory disability in later childhood, neonatal hypoglycaemia, adiposity, diabetes). </p> <p><b>Metformin versus glibenclamide</b> </p> <p>There was no evidence of a difference between metformin‐ and glibenclamide‐treated groups for the risk of hypertensive disorders of pregnancy (RR 0.70, 95% CI 0.38 to 1.30; three studies, 508 women, moderate‐quality evidence), birth by caesarean section (average RR 1.20, 95% CI 1.20; 95% CI 0.83 to 1.72, four studies, 554 women, I<sup>2</sup> = 61%, Tau<sup>2</sup> = 0.07 low‐quality evidence), induction of labour (0.81, 95% CI 0.61 to 1.07; one study, 159 women; low‐quality evidence) or perineal trauma (RR 1.67, 95% CI 0.22 to 12.52; two studies, 158 women; low‐quality evidence). No data were reported for development of type 2 diabetes or other pre‐specified GRADE maternal outcomes (return to pre‐pregnancy weight, postnatal depression). For the infant there was no evidence of a difference between the metformin‐ and glibenclamide‐exposed groups for the risk of being born LGA (average RR 0.67, 95% CI 0.24 to 1.83; two studies, 246 infants, I<sup>2</sup> = 54%, Tau<sup>2</sup> = 0.30 low‐quality evidence). Metformin was associated with a decrease in a death or serious morbidity composite (RR 0.54, 95% CI 0.31 to 0.94; one study, 159 infants, low‐quality evidence). There was no clear difference between groups for neonatal hypoglycaemia (RR 0.86, 95% CI 0.42 to 1.77; four studies, 554 infants, low‐quality evidence) or perinatal mortality (RR 0.92, 95% CI 0.06 to 14.55, two studies, 359 infants). No data were reported for neurosensory disability in later childhood or for adiposity or diabetes. </p> <p><b>Glibenclamide versus acarbose</b> </p> <p>There was no evidence of a difference between glibenclamide and acarbose from one study (43 women) for any of their maternal or infant primary outcomes (caesarean section, RR 0.95, 95% CI 0.53 to 1.70; low‐quality evidence; perinatal mortality ‐ no events; low‐quality evidence; LGA , RR 2.38, 95% CI 0.54 to 10.46; low‐quality evidence). There was no evidence of a difference between glibenclamide and acarbose for neonatal hypoglycaemia (RR 6.33, 95% CI 0.87 to 46.32; low‐quality evidence). There were no data reported for other pre‐specified GRADE or primary maternal outcomes (hypertensive disorders of pregnancy, development of type 2 diabetes, perineal trauma, return to pre‐pregnancy weight, postnatal depression, induction of labour) or neonatal outcomes (death or serious morbidity composite, adiposity or diabetes). </p> </section> <section id="CD011967-sec-0007"> <h3 class="title" id="CD011967-sec-0007">Authors' conclusions</h3> <p>There were insufficient data comparing oral anti‐diabetic pharmacological therapies with placebo/standard care (lifestyle advice) to inform clinical practice. There was insufficient high‐quality evidence to be able to draw any meaningful conclusions as to the benefits of one oral anti‐diabetic pharmacological therapy over another due to limited reporting of data for the primary and secondary outcomes in this review. Short‐ and long‐term clinical outcomes for this review were inadequately reported or not reported. Current choice of oral anti‐diabetic pharmacological therapy appears to be based on clinical preference, availability and national clinical practice guidelines. </p> <p>The benefits and potential harms of one oral anti‐diabetic pharmacological therapy compared with another, or compared with placebo/standard care remains unclear and requires further research. Future trials should attempt to report on the core outcomes suggested in this review, in particular long‐term outcomes for the woman and the infant that have been poorly reported to date, women's experiences and cost benefit. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011967-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011967-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011967-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011967-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011967-abs-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011967-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011967-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011967-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011967-abs-0005" lang="en"> <h3>Oral medication for the treatment of women with gestational diabetes</h3> <p><b>What is the issue?</b> </p> <p>Globally the number of women being diagnosed with gestational diabetes mellitus (GDM) is increasing. GDM is an intolerance to glucose leading to high blood sugars, first recognised during pregnancy and usually resolving after birth. Standard care involves lifestyle advice on diet and exercise. Treatment for some women includes oral anti‐diabetic medications, such as metformin and glibenclamide, which are an alternative to, or can be used alongside, insulin to control the blood sugar. This review aimed to investigate benefits of taking oral medication to treat GDM in pregnant women. Another Cochrane Review compares the effects of insulin with oral anti‐diabetic pharmacological therapies <i>(</i><a href="http://Brown 2016" target="_blank">Brown 2016</a>). </p> <p><b>Why is this important?</b> </p> <p>Women diagnosed with GDM are at a greater risk of experiencing complications such as high blood pressure during pregnancy and at birth. They have an increased risk of developing diabetes later in life. The babies of women who have been diagnosed with GDM can be larger than normal and this can cause injuries to the mother and the baby at birth. The birth is more likely to be induced or the baby born by caesarean section. These babies are at risk of developing diabetes as children or young adults. Finding the best medications to treat the women and prevent the complications that are linked to GDM is therefore important. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for studies on 14 May 2016. We included 11 randomised controlled trials involving 1487 mothers and their babies (but only eight trials contributed data to our analyses). The evidence was limited by the quality and number of studies and we advise caution when looking at the results. </p> <p>The criteria for diagnosis of GDM and treatment targets varied between studies, and each outcome is based on few studies with low numbers of women. Three studies compared oral medication with placebo/standard care but the following findings are from a single study (375 women). The quality of the evidence was very low or low. We found no differences between the oral medication and placebo group for the risk of high blood pressure, birth by caesarean section, induction of labour or perineal trauma. The number of babies born large‐for‐gestational age, with low blood sugars or dying at birth was not clearly different between the groups. Two studies (434 women) reported no difference in the need for insulin between the oral medication and placebo group. </p> <p>Six studies compared metformin with glibenclamide. The quality of the evidence was very low to moderate. We found no difference between metformin and glibenclamide for the risk of high blood pressure (three studies, 508 women, moderate‐quality evidence), birth by caesarean section (four studies, 554 women, low‐quality evidence), perineal trauma (two studies, 308 women, low‐quality evidence) or induction of labour (one study, 159 women, low‐quality evidence). We found no difference between metformin and glibenclamide for the baby having low blood sugars (four studies, 554 infants, low‐quality evidence), being born large‐for‐gestational age (two studies, 246 infants) or dying at birth (all low‐ or very low‐quality evidence). In one study, the babies of the mothers taking metformin were at reduced risk of having any serious outcome (low blood sugar, jaundice, being born large, breathing problems, injury at birth or death combined) (low‐quality evidence). One small study (43 women) comparing glibenclamide with acarbose reported no differences in outcomes for mothers or their babies. </p> <p>None of the included studies provided any data on many of the outcomes pre‐specified in this review, including long‐term outcomes for the mother or for the baby as a child or an adult. </p> <p><b>What does this mean?</b> </p> <p>There is not enough high‐quality evidence available to guide us on if oral medication has better outcomes for women with gestational diabetes, and their babies, compared with a placebo or if one oral medication has better health outcomes than another oral medication. Because we are still unclear, further research is needed. Future studies should be encouraged to report on the outcomes suggested in this review and in particular the long‐term outcomes for the woman and the infant that have been poorly reported to date. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011967-sec-0237" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-sec-0237">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-sec-0300">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011967-sec-0237"></div> <h3 class="title" id="CD011967-sec-0238">Implications for practice</h3> <section id="CD011967-sec-0238"> <p>Due to lack of data reported for the outcomes of interest in this review, the evidence is uncertain as to whether one oral anti‐diabetic pharmacological therapy is safer or more effective than another. The choice in use of oral anti‐diabetic pharmacological therapy is likely dependent on factors such as preference of the woman, availability and national clinical practice guidelines. </p> </section> <h3 class="title" id="CD011967-sec-0239">Implications for research</h3> <section id="CD011967-sec-0239"> <p>Oral anti‐diabetic pharmacological therapies are becoming more widely used for treating women with gestational diabetes mellitus (GDM). Uncertainty remains due to the limited evidence to support the use of one oral anti‐diabetic pharmacological therapy over another. </p> <p>Future research trials should be encouraged to report on the core outcomes suggested in this review and in particular the long‐term outcomes for the woman and the infant that have been poorly reported to date. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011967-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011967-sec-0036"></div> <div class="table" id="CD011967-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy. </p> <p><b>Setting</b> : Medical Centre, USA.<br/> <b>Intervention:</b> oral anti‐diabetic pharmacological therapy (glibenclamide)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral anti‐diabetic pharmacological therapies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy ‐ (any type)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/> (135 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.81 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caearean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/> (285 to 483) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.79 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perineal trauma</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000<br/> (0 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98<br/> (0.06 to 15.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>abcd</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Event rates were low 1/189 for anti‐diabetic pharmacological therapy and 1/186 in the control (placebo) group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Induction of labour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>222 per 1000<br/> (149 to 331) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.18<br/> (0.79 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ we did not find a published protocol and there were more outcomes reported in the published paper than were listed in the trial registration document ‐ downgraded 1 level.<br/> <sup>b</sup>Generalisability ‐ in this single study 93% of participants were Hispanic women. Results may not be generalisable to other populations ‐ downgraded 1 level.<br/> <sup>c</sup>Imprecision ‐ evidence based on a single study ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ wide confidence intervals crossing the line of no effect and low event rates suggestive of imprecision ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011967-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants of women diagnosed with gestational diabetes </p> <p>Setting: Medical Centre, USA<br/> <b>Intervention:</b> oral anti‐diabetic pharmacological therapies (glibenclamide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral anti‐diabetic pharmacological therapies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large‐for‐gestational age</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/> (60 to 187) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.51 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perinatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (4 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.97<br/> (0.36 to 10.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abcd</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Event rates were low with 4/189 for oral anti‐diabetic pharmacological therapy and 2/186 for placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity (neonate, child, adult) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes (child, adult) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ we did not find a published protocol and there were more outcomes reported in the published paper than were listed in the trial registration document ‐ downgraded 1 level.<br/> <sup>b</sup>This single trial comprised 93% Hispanic women. The results may not be generalisable ‐ downgraded 1 level.<br/> <sup>c</sup>Imprecision ‐ evidence was based on a single trial only ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecison ‐ wide confidence intervals crossing the line of no effect and low event rates ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011967-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin versus glibenclamide ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin versus glibenclamide ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes </p> <p><b>Setting:</b> trials conducted in Brazil, India and the USA<br/> <b>Intervention:</b> metformin<br/> <b>Comparison:</b> glibenclamide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (33 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.38 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/> (325 to 674) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20<br/> (0.83 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>bc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had pre‐specified development of type 2 diabetes as an outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perineal trauma</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (1 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67<br/> (0.22 to 12.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ad</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note low event rates (2/154 for metformin and 1/154 for glibenclamide</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had return to pre‐pregnancy weight as a pre‐specified outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had postnatal depression as a pre‐specified outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induction of labour</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>496 per 1000<br/> (374 to 655) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.61 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ae</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ all studies were open label ‐ downgraded 1 level.<br/> <sup>b</sup>Risk of bias ‐ 3 of the 4 studies were open label and 3 of 4 studies were unclear for blinding of outcome assessors. 2 studies reported additional outcomes that were not pre‐specified ‐ downgraded 1 level.<br/> <sup>c</sup>Inconsistency ‐ heterogeneity was high, I<sup>2</sup> = 61% downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ wide confidence intervals along with low event rates suggest imprecision ‐ downgraded 1 level.<br/> <sup>e</sup>Imprecision ‐ evidence was based on a single trial ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011967-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin versus glibenclamide ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin versus glibenclamide ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Infants of women diagnosed with gestational diabetes </p> <p><b>Setting:</b> trials conducted in Brazil, India and the USA<br/> <b>Intervention:</b> metformin<br/> <b>Comparison:</b> glibenclamide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>193 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>129 per 1000<br/> (46 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67<br/> (0.24 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.06 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that event rates were very low. 1 study had no event of perinatal death in either the metformin nor the glibenclamide group. The second study had 1 death in each group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (109 to 329) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54<br/> (0.31 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (20 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.42 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ae</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified adiposity as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified diabetes as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified neurosensory disability as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ allocation concealment was unclear in 1 study. 1 study was open label ‐ downgraded 1 level.<br/> <sup>b</sup>Inconsistency ‐ heterogeneity was I<sup>2</sup>= 54%, which could not be explained by the diagnostic criteria used ‐ downgraded 1 level.<br/> <sup>c</sup>Risk of bias ‐ includes open label study/studies with no evidence of blinding of participants or researchers ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ evidence based on a single small study ‐ downgraded 1 level.<br/> <sup>e</sup>Imprecision ‐ event rates low (&lt; 30) ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011967-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glibenclamide versus acarbose ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Glibenclamide versus acarbose ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy </p> <p><b>Setting:</b> Maternity hospital, Brazil<br/> <b>Intervention:</b> Glibenclamide<br/> <b>Comparison:</b> Acarbose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acarbose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other oral anti‐diabetic agent</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>526 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/> (279 to 895) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.53 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perineal trauma ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induction of labour ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Method of randomisation was unclear and the study was open‐label ‐ downgraded ‐1 level.<br/> <sup>b</sup>Evidence based on a single small study ‐ downgraded ‐1 level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011967-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glibenclamide versus acarbose ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Glibenclamide versus acarbose ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gestational diabetes </p> <p><b>Setting:</b> maternity hospital, Brazil<br/> <b>Intervention:</b> glibenclamide<br/> <b>Comparison:</b> acarbose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acarbose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>251 per 1000<br/> (57 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.38<br/> (0.54 to 10.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events were reported in either group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53/1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333/1000</p> <p>(46 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.33 (0.87 to 46.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low event rates and sample size (8/24 in glibenclamide group and 1/19 in acarbose group) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ evidence of selective reporting ‐ downgraded 1 level.<br/> <sup>b</sup>Imprecision ‐ evidence based on a single small study with wide confidence intervals ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011967-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-sec-0259">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011967-sec-0037"></div> <p>The original review by Alwan and colleagues, <i>Treatments for gestational diabetes</i> (<a href="./references#CD011967-bbs2-0105" title="AlwanN , TuffnellDJ , WestJ . Treatments for gestational diabetes. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003395.pub2] ">Alwan 2009</a>) has been split into three new review titles reflecting the complexity of treating women with gestational diabetes. </p> <p> <ul id="CD011967-list-0001"> <li> <p><i>Lifestyle interventions for the treatment of women with gestational diabetes mellitus</i> (<a href="./references#CD011967-bbs2-0030" title="BrownJ , AlwanNA , WestJ , BrownS , McKinlayCJD , FarrarD , et al. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD011970] ">Brown 2015</a>) </p> </li> <li> <p><i>Oral anti‐diabetic pharmacological therapies for the treatment of women with gestational diabetes mellitus</i> (this review) </p> </li> <li> <p><i>Insulin for the treatment of women with gestational diabetes mellitus</i> (<a href="./references#CD011967-bbs2-0031" title="BrownJ , GrzeskowiakL , WilliamsonK , DownieMR , CrowtherCA . Insulin for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD012037] ">Brown 2016</a>) </p> </li> </ul> </p> <p>There will be similarities in the background, methods and outcomes between these three systematic reviews. Portions of the methods section of this review are based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD011967-sec-0038"> <h3 class="title" id="CD011967-sec-0038">Description of the condition</h3> <p>Gestational diabetes mellitus (GDM) often referred to as gestational diabetes can be defined as "glucose intolerance or hyperglycaemia (high blood glucose concentration) with onset or first recognition during pregnancy" (<a href="./references#CD011967-bbs2-0102" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Geneva, Switzerland: WHO, 1999. ">WHO 1999</a>). GDM occurs when the body is unable to make enough insulin to meet the extra needs in pregnancy. The high blood sugars associated with GDM will return to normal after the birth of the baby. However, there are currently no universally accepted diagnostic criteria (<a href="./references#CD011967-bbs2-0020" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician‐gynecologists. Obstetrics &amp; Gynecology2013;122(2 Pt 1):406‐16. ">ACOG 2013</a>; <a href="./references#CD011967-bbs2-0038" title="CoustanDR , LoweLP , MetzgerBE , DyerAR , International Association of Diabetes and Pregnancy Study Groups. The hyperglycemia and adverse pregnancy outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. American Journal of Obstetrics and Gynecology2010;202(6):654.e1‐654.e6. ">Coustan 2010</a>; <a href="./references#CD011967-bbs2-0052" title="The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">HAPO 2008</a>; <a href="./references#CD011967-bbs2-0060" title="HoffmanL , NolanC , WilsonJD , OatsJJ , Simmons D. The Australasian Diabetes in Pregnancy Society. Gestational diabetes mellitus‐management guidelines. Medical Journal of Australia1998;169(2):93‐7. ">Hoffman 1998</a>; <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a>; <a href="./references#CD011967-bbs2-0074" title="MetzgerBE , CoustanDR . Summary and recommendations of the Fourth International Workshop‐Conference on Gestational Diabetes Mellitus. Diabetes Care1998;21(Suppl 2):B161‐7. ">Metzger 1998</a>; <a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a>). GDM may include previously undetected type 1 diabetes, type 2 diabetes or diabetes presenting only during pregnancy (<a href="./references#CD011967-bbs2-0052" title="The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">HAPO 2008</a>; <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a>; <a href="./references#CD011967-bbs2-0074" title="MetzgerBE , CoustanDR . Summary and recommendations of the Fourth International Workshop‐Conference on Gestational Diabetes Mellitus. Diabetes Care1998;21(Suppl 2):B161‐7. ">Metzger 1998</a>; <a href="./references#CD011967-bbs2-0080" title="NankervisA , McIntyreHD , MosesR , RossGP , CallawayL , PorterC , et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf(accessed 2014). ">Nankervis 2014</a>; <a href="./references#CD011967-bbs2-0103" title="World Health Organization. WHO Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Report WHO/NMH/MND/13.2. Geneva, Switzerland: WHO, 2014. ">WHO 2014</a>). </p> <p>GDM is one of the most common pregnancy complications and the prevalence is rising worldwide with 1% to 36% of pregnancies being affected (<a href="./references#CD011967-bbs2-0027" title="BottalicoJN . Recurrent gestational diabetes: risk factors, diagnosis, management, and implications. Seminars in Perinatology2007;31(3):176‐84. ">Bottalico 2007</a>; <a href="./references#CD011967-bbs2-0040" title="CundyT , AckermannE , RyanEA . Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ2014;348:g1567. ">Cundy 2014</a>; <a href="./references#CD011967-bbs2-0044" title="DuranA , SaenzS , TorrejonM , BordiuE , delValleL , GalindoM , et al. Introduction of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: the St. Carlos gestational diabetes study. Diabetes Care2014;37:2442‐50. ">Duran 2014</a>; <a href="./references#CD011967-bbs2-0048" title="FerraraA . Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care2007;30(Suppl 2):S141‐S146. ">Ferrara 2007</a>; <a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a>; <a href="./references#CD011967-bbs2-0089" title="RagnarsdottirLH , ConroyS . Development of macrosomia resulting from gestational diabetes mellitus: physiology and social determinants of health. Advances in Neonatal Care2010;10(1):7‐12. ">Ragnarsdottir 2010</a>; <a href="./references#CD011967-bbs2-0099" title="TranTS , HirstJE , DoMA , MorrisJM , JeffreyHE . Early prediction of gestational diabetes mellitus in Vietnam: clinical impact of currently recommended diagnostic criteria. Diabetes Care2013;36(3):618‐24. ">Tran 2013</a>). The prevalence of GDM is likely to continue to increase along with the increasing prevalence of maternal obesity and associated type 2 diabetes (<a href="./references#CD011967-bbs2-0027" title="BottalicoJN . Recurrent gestational diabetes: risk factors, diagnosis, management, and implications. Seminars in Perinatology2007;31(3):176‐84. ">Bottalico 2007</a>; <a href="./references#CD011967-bbs2-0079" title="MullaWR , HenryTQ , HomkoCJ . Gestational diabetes screening after HAPO: has anything changed?. Current Diabetes Reports2010;10(3):224‐8. ">Mulla 2010</a>; <a href="./references#CD011967-bbs2-0085" title="PetryCJ . Gestational diabetes: risk factors and recent advances in its genetics and treatment. British Journal of Nutrition2010;104(6):775‐87. ">Petry 2010</a>). </p> <p>A variety of factors have been associated with an increased risk of developing GDM. Non‐modifiable risk factors include advanced maternal age (<a href="./references#CD011967-bbs2-0034" title="ChamberlainC , McNamaraB , WilliamsE , YoreD , OldenburgB , OatsJ , et al. Diabetes in pregnancy among indigenous women in Australia, Canada, New Zealand and the United States. Diabetes/Metabolism Research Reviews2013;29(4):241‐56. ">Chamberlain 2013</a>; <a href="./references#CD011967-bbs2-0077" title="MorissetAS , St‐YvesA , VeilletteJ , WeisnagelSJ , TchernofA , RobitailleJ . Prevention of gestational diabetes mellitus: a review of studies on weight management. Diabetes/Metabolism Research and Reviews2010;26(1):17‐25. ">Morisset 2010</a>), high parity, non‐white race or ethnicity (in particular South Asian, Middle Eastern), family history of diabetes, maternal high or low birthweight, polycystic ovarian syndrome (<a href="./references#CD011967-bbs2-0041" title="CyprykK , SzymczakW , CzupryniakL , SobczakM , LewinskiA . Gestational diabetes mellitus ‐ an analysis of risk factors. Endokrynologia Polska (Warszawa)2008;59(5):393‐7. ">Cypryk 2008</a>; <a href="./references#CD011967-bbs2-0085" title="PetryCJ . Gestational diabetes: risk factors and recent advances in its genetics and treatment. British Journal of Nutrition2010;104(6):775‐87. ">Petry 2010</a>; <a href="./references#CD011967-bbs2-0097" title="SolomonCG , WillettWC , CareyVJ , Rich‐EdwardsJ , HunterDJ , ColditzGA , et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA1997;278(13):1078‐83. ">Solomon 1997</a>), a history of having a previous macrosomic infant (birthweight 4000 g or more) and previous history of GDM (<a href="./references#CD011967-bbs2-0085" title="PetryCJ . Gestational diabetes: risk factors and recent advances in its genetics and treatment. British Journal of Nutrition2010;104(6):775‐87. ">Petry 2010</a>). </p> <p>Modifiable risk factors include physical inactivity (<a href="./references#CD011967-bbs2-0035" title="Chasan‐TaberL , SchmidtMD , PekowP , SternfeldB , MansonJE , SolomonCG , et al. Physical activity and gestational diabetes mellitus among Hispanic women. Journal of Women's Health2008;17(6):999‐1008. ">Chasan‐Taber 2008</a>), having a low‐fibre and high‐glycaemic load diet (<a href="./references#CD011967-bbs2-0104" title="ZhangC , LiuS , SolomonCG , HuFB . Dietary fiber intake, dietary glycemic load, and the risk for gestational diabetes mellitus. Diabetes Care2006;29(10):2223‐30. ">Zhang 2006</a>), maternal overweight (body mass index (BMI) equal to or greater than 25 kg/m²) or obesity (equal to or greater than 30 kg/m²) (<a href="./references#CD011967-bbs2-0068" title="KimSY , EnglandL , WilsonHG , BishC , SattenGA , DietzP . Percentage of gestational diabetes attributable to overweight and obesity. American Journal of Public Health2010;100(6):1047‐52. ">Kim 2010</a>) and excessive weight gain during pregnancy, especially for those who are already overweight or obese (<a href="./references#CD011967-bbs2-0054" title="HeddersonMM , GundersonEP , FerraraA . Gestational weight gain and risk of gestational diabetes mellitus. Obstetrics &amp; Gynecology2010;115(3):597‐604. ">Hedderson 2010</a>). </p> <section id="CD011967-sec-0039"> <h4 class="title">Pathophysiology of gestational diabetes</h4> <p>Normal pregnancy is associated with significant changes in maternal metabolism (<a href="./references#CD011967-bbs2-0070" title="LainKY , CatalanoPM . Metabolic changes in pregnancy. Clinical Obstetrics and Gynecology2007;50(4):938‐48. ">Lain 2007</a>). In early pregnancy, oestrogen and progesterone stimulate maternal beta‐cell hyperplasia and insulin secretion, which promotes maternal nutrient storage (adipose and hepatic glycogen) to support later fetal growth. At this stage, insulin sensitivity is maintained or may even increase. However, as pregnancy progresses whole‐body insulin sensitivity steadily decreases, such that by the third trimester it is reduced by almost half (<a href="./references#CD011967-bbs2-0025" title="BarbourLA , McCurdyCE , HernandezTL , KirwanJP , CatalanoPM , FriedmanJE . Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care2007;30(Suppl 2):S111‐S119. ">Barbour 2007</a>). Several factors contribute to this, including placental hormones (human placental lactogen and placental growth hormone), cytokines released from adipocytes (IL‐6, TNF‐alpha), increased free fatty acids and lower adiponectin concentrations (<a href="./references#CD011967-bbs2-0037" title="ClappJF . Effects of diet and exercise on insulin resistance during pregnancy. Metabolic Syndrome and Related Disorders2006;4(2):84‐90. ">Clapp 2006</a>; <a href="./references#CD011967-bbs2-0043" title="DevliegerR , CasteelsK , VanAsscheFA . Reduced adaptation of the pancreatic B cells during pregnancy is the major causal factor for gestational diabetes: current knowledge and metabolic effects on the offspring. Acta Obstetricia et Gynecologica Scandinavica2008;87(12):1266‐70. ">Devlieger 2008</a>). This results in decreased post‐prandial peripheral glucose disposal by up to 40% to 60% (<a href="./references#CD011967-bbs2-0025" title="BarbourLA , McCurdyCE , HernandezTL , KirwanJP , CatalanoPM , FriedmanJE . Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care2007;30(Suppl 2):S111‐S119. ">Barbour 2007</a>). Because glucose is transported to the fetus by facilitated diffusion, this state of physiological insulin resistance promotes fetal glucose uptake, a principal oxidative fuel and carbon source for the growing fetus. In normal pregnancy, maternal glycaemia is maintained by a significant increase in insulin secretion of up to 200% to 250% (<a href="./references#CD011967-bbs2-0025" title="BarbourLA , McCurdyCE , HernandezTL , KirwanJP , CatalanoPM , FriedmanJE . Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care2007;30(Suppl 2):S111‐S119. ">Barbour 2007</a>; <a href="./references#CD011967-bbs2-0070" title="LainKY , CatalanoPM . Metabolic changes in pregnancy. Clinical Obstetrics and Gynecology2007;50(4):938‐48. ">Lain 2007</a>; <a href="./references#CD011967-bbs2-0098" title="Suman RaoPN , ShashidharA , AshokC . In utero fuel homeostasis: lessons for a clinician. Indian Journal of Endocrinology and Metabolism2013;17(1):60‐8. ">Suman Rao 2013</a>). </p> <p>Regulation of fetal glucose metabolism requires (1) the maintenance of maternal glucose concentration through increasing maternal glucose production, and at the same time, developing maternal glucose intolerance and insulin resistance, (2) transfer of glucose to the fetus across the placenta and (3) production of fetal insulin and uptake of glucose into adipose tissue and skeletal muscle (<a href="./references#CD011967-bbs2-0098" title="Suman RaoPN , ShashidharA , AshokC . In utero fuel homeostasis: lessons for a clinician. Indian Journal of Endocrinology and Metabolism2013;17(1):60‐8. ">Suman Rao 2013</a>). </p> <p>Women with GDM have further reductions in insulin signalling, and glucose uptake is decreased beyond that of normal pregnancy (<a href="./references#CD011967-bbs2-0025" title="BarbourLA , McCurdyCE , HernandezTL , KirwanJP , CatalanoPM , FriedmanJE . Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care2007;30(Suppl 2):S111‐S119. ">Barbour 2007</a>). This results in glucose intolerance, though glycaemia in pregnancy represents a continuum. In GDM, the steeper maternal‐fetal glucose gradient, especially post‐prandial, leads to increased fetal glucose uptake which stimulates fetal insulin secretion. Insulin is a key fetal anabolic hormone and hyperinsulinaemia promotes fetal overgrowth leading to large‐for‐gestational age (LGA) infants, macrosomia, and possible organ damage (<a href="./references#CD011967-bbs2-0033" title="CatalanoPMA , Huston‐PresleyTL , AminiSB . Increased fetal adiposity: a very sensitive marker of abnormal in utero development. American Journal of Obstetrics &amp; Gynecology2003;189(6):1698‐704. ">Catalano 2003</a>; <a href="./references#CD011967-bbs2-0064" title="JuH , RumboldAR , WillsonKJ , CrowtherCA . Effect of birth weight on adverse obstetric outcomes in vaginal birth after caesarean delivery. BMC Pregnancy and Childbirth2008;8:31. ">Ju 2008</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>; <a href="./references#CD011967-bbs2-0090" title="ReeceEA , LeguizamonG , WiznitzerA . Gestational diabetes: the need for a common ground. Lancet2009;373(9677):1789‐97. ">Reece 2009</a>). </p> <p>Women with GDM also have increased circulating inflammatory cytokines and lower adiponectin concentrations leading to increased lipolysis and fatty acid concentrations. Placental transfer of free fatty acids contributes to increased fetal adiposity, independent of glucose uptake (<a href="./references#CD011967-bbs2-0069" title="KnoppRH , BergelinRO , WahlPW , WaldenCE . Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes1985;34(Suppl 2):71‐7. ">Knopp 1985</a>). Thus, even women with well‐controlled GDM still have increased risk of fetal macrosomia (<a href="./references#CD011967-bbs2-0073" title="LangerO , YogevY , MostO , XenakisEM . Gestational diabetes: the consequences of not treating. American Journal of Obstetrics and Gynecology2005;192(4):989‐97. ">Langer 2005</a>). </p> </section> <section id="CD011967-sec-0040"> <h4 class="title">Screening and diagnosis of GDM</h4> <p>Regardless of whether universal or selective (risk‐factor), screening with a 50 g oral glucose challenge test is used, diagnosis of GDM is usually based on either a 75 g two‐hour oral glucose tolerance test (OGTT) or a 100 g three‐hour OGTT (<a href="./references#CD011967-bbs2-0021" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2013;36(Suppl 1):567‐74. ">ADA 2013</a>; <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a>; <a href="./references#CD011967-bbs2-0080" title="NankervisA , McIntyreHD , MosesR , RossGP , CallawayL , PorterC , et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf(accessed 2014). ">Nankervis 2014</a>; <a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a>; <a href="./references#CD011967-bbs2-0102" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Geneva, Switzerland: WHO, 1999. ">WHO 1999</a>). Recommendations regarding diagnostic criteria vary nationally and internationally (<a href="#CD011967-tbl-0007">Table 1</a>), and these diagnostic criteria have changed over time, sometimes due to changing understanding about the effects of hyperglycaemia on pregnancy and infant outcomes (<a href="./references#CD011967-bbs2-0038" title="CoustanDR , LoweLP , MetzgerBE , DyerAR , International Association of Diabetes and Pregnancy Study Groups. The hyperglycemia and adverse pregnancy outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. American Journal of Obstetrics and Gynecology2010;202(6):654.e1‐654.e6. ">Coustan 2010</a>), but also because of a lack of evidence clearly demonstrating the clinical and cost‐effectiveness of one criterion over another. </p> <div class="table" id="CD011967-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Examples of diagnostic criteria for gestational diabetes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organisation/professional body</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Screening and diagnostic criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1‐hour oral glucose challenge test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oral glucose tolerance tes</b>t </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fasting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1 hour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2 hour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 hour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0021" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2013;36(Suppl 1):567‐74. ">ADA 2013</a><sup>a</sup>, <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a><sup>a</sup>, ADIPS 2013 (<a href="./references#CD011967-bbs2-0080" title="NankervisA , McIntyreHD , MosesR , RossGP , CallawayL , PorterC , et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf(accessed 2014). ">Nankervis 2014</a>)<sup>a</sup>, <a href="./references#CD011967-bbs2-0103" title="World Health Organization. WHO Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Report WHO/NMH/MND/13.2. Geneva, Switzerland: WHO, 2014. ">WHO 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.1 mmol/L</p> <p>(≥ 92 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10 mmol/L</p> <p>(≥ 180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.5 mmol/L</p> <p>(≥ 153 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD011967-bbs2-0020" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician‐gynecologists. Obstetrics &amp; Gynecology2013;122(2 Pt 1):406‐16. ">ACOG 2013</a> </p> <p>Carpenter and Coustan<sup>b</sup> </p> <p>National Diabetes Data Group<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>(&gt; 7.2 mmol/L;</p> <p>&gt; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.3 mmol/L</p> <p>(≥ 95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10 mmol/L</p> <p>(≥180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.6 mmol/L</p> <p>(≥ 155 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.8 mmol/L</p> <p>(≥ 140 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>(&gt; 7.8 mmol/L; &gt; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.8 mmol/L</p> <p>(≥ 105 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10.6 mmol/L</p> <p>(≥ 190 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.2 mmol/L</p> <p>(≥ 165 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.0 mmol/L</p> <p>(≥ 145 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0032" title="Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes2013;37 (Suppl 1):S1‐S212. ">Canadian Diabetes Association 2013</a> </p> <p>either<sup>a</sup> </p> <p>or<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.3 mmol/L</p> <p>(≥ 95 mg/dL)</p> <p>≥ 5.1 mmol/L</p> <p>(≥ 92 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10.6 mmol/L</p> <p>(≥ 190 mg/dL)</p> <p>≥ 10 mmol/L</p> <p>(≥ 180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.0 mmol/L</p> <p>≥ 8.5 mmol/L</p> <p>(≥ 153 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.6 mmol/L</p> <p>(≥ 101 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.8 mmol/L</p> <p>(≥ 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0081" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline 63. London: NICE, 2008. ">NICE 2008</a>; <a href="./references#CD011967-bbs2-0102" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Geneva, Switzerland: WHO, 1999. ">WHO 1999</a>; <a href="./references#CD011967-bbs2-0060" title="HoffmanL , NolanC , WilsonJD , OatsJJ , Simmons D. The Australasian Diabetes in Pregnancy Society. Gestational diabetes mellitus‐management guidelines. Medical Journal of Australia1998;169(2):93‐7. ">Hoffman 1998</a> (ADIPS)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.0 mmol/L</p> <p>(≥ 126 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 11.1 mmol/L</p> <p>(≥ 200 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New Zealand <a href="./references#CD011967-bbs2-0076" title="Ministry of Health. Screening, Diagnosis and Management of Gestational Diabetes in New Zealand: A Clinical Practice Guideline. Wellington: Ministry of Health, 2014. ">Ministry of Health 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g if HbA1c &lt; 41 mmol/mol</p> <p>(≥ 7.8 mmol/L; ≥ 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.5 mmol/L</p> <p>(≥ 99 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.0 mmol/L</p> <p>(≥ 162 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADA: American Diabetes Association<br/> IADPSG: International Association of the Diabetes and Pregnancy Study Groups<br/> ADIPS: Australasian Diabetes in Pregnancy Society<br/> ACOG: American College of Obstetrics and Gynecology<br/> NICE: National Institute for Health and Care Excellence<br/> <sup>a</sup>1 abnormal result required for diagnosis<br/> <sup>b</sup>2 or more abnormal results required for diagnosis </p> </div> </div> <p>The Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study (<a href="./references#CD011967-bbs2-0052" title="The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">HAPO 2008</a>), a large, international observational study reported graded linear associations in the odds of several GDM‐associated adverse outcomes and glucose levels at OGTT, with no clear threshold identified at which risk increased substantially. The International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommended diagnostic criteria using data from the HAPO study (<a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a>). Applying the IADPSG criteria in most health environments will increase the number of women with GDM. A study conducted in Vietnam showed that depending on the criteria used, the diagnosis of GDM varied between 5.9% (American Diabetes Association ‐ ADA), 20.4% (International Association of Diabetes in Pregnancy Study Groups ‐ IADPSG), 20.8% (Australasian Diabetes in Pregnancy Society ‐ ADIPS), and up to 24.3% (World Health Organization ‐ WHO) (<a href="./references#CD011967-bbs2-0099" title="TranTS , HirstJE , DoMA , MorrisJM , JeffreyHE . Early prediction of gestational diabetes mellitus in Vietnam: clinical impact of currently recommended diagnostic criteria. Diabetes Care2013;36(3):618‐24. ">Tran 2013</a>). A Bulgarian study also reported differences in prevalence based on the diagnostic criteria ranging from 10.8% (European Association for the Study of Diabetes ‐ EASD), 13.5% (ADA), 16.2% (New Zealand Society for the Study of Diabetes ‐ NZSSD), 17.1% (WHO), 21.2% (ADIPS), 31.6% (IADPSG) (<a href="./references#CD011967-bbs2-0028" title="BoyadzhievaMV , AtanasovaI , ZacharievaS , TankovaT , DimitrovaV . Comparative analysis of current diagnostic criteria for gestational diabetes mellitus. Obstetric Medicine2012;5:71‐7. ">Boyadzhieva 2012</a>). </p> </section> <section id="CD011967-sec-0041"> <h4 class="title">Clinical outcomes for women with gestational diabetes</h4> <p>Adverse outcomes have been consistently reported at higher rates in women diagnosed with GDM and their infants compared to women without GDM (<a href="./references#CD011967-bbs2-0039" title="CrowtherCA , HillerJE , MossJR , McPheeAJ , JeffriesWS , RobinsonJS , et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England Journal of Medicine2005;352(24):2477‐86. ">Crowther 2005</a>; <a href="./references#CD011967-bbs2-0071" title="LandonMB , SpongCY , ThomE , CarpenterMW , RaminSM , CaseyB , et al. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine2009;361(14):1339‐48. ">Landon 2009</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>; <a href="./references#CD011967-bbs2-0090" title="ReeceEA , LeguizamonG , WiznitzerA . Gestational diabetes: the need for a common ground. Lancet2009;373(9677):1789‐97. ">Reece 2009</a>). </p> <p>Women with GDM have an increased risk of developing pre‐eclampsia, are more likely to have their labour induced (<a href="./references#CD011967-bbs2-0023" title="AnderbergE , KallenK , BerntorpK . The impact of gestational diabetes mellitus on pregnancy outcome comparing different cut‐off criteria for abnormal glucose tolerance. Acta Obstetricia et Gynecologica Scandinavica2010;89(12):1532‐7. ">Anderberg 2010</a>; <a href="./references#CD011967-bbs2-0039" title="CrowtherCA , HillerJE , MossJR , McPheeAJ , JeffriesWS , RobinsonJS , et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England Journal of Medicine2005;352(24):2477‐86. ">Crowther 2005</a>; <a href="./references#CD011967-bbs2-0064" title="JuH , RumboldAR , WillsonKJ , CrowtherCA . Effect of birth weight on adverse obstetric outcomes in vaginal birth after caesarean delivery. BMC Pregnancy and Childbirth2008;8:31. ">Ju 2008</a>; <a href="./references#CD011967-bbs2-0071" title="LandonMB , SpongCY , ThomE , CarpenterMW , RaminSM , CaseyB , et al. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine2009;361(14):1339‐48. ">Landon 2009</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>), and give birth by caesarean section (<a href="./references#CD011967-bbs2-0071" title="LandonMB , SpongCY , ThomE , CarpenterMW , RaminSM , CaseyB , et al. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine2009;361(14):1339‐48. ">Landon 2009</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>). The incidence of uterine rupture, shoulder dystocia and perineal lacerations are increased in women with GDM due to the increased likelihood of having a LGA or macrosomic baby (<a href="./references#CD011967-bbs2-0063" title="JastrowN , RobergeS , GauthierRJ , LarocheL , DuperronL , BrassardN , et al. Effect of birth weight on adverse obstetric outcomes in vaginal birth after cesarean delivery. Obstetrics &amp; Gynecology2010;115(2 Pt 1):338‐43. ">Jastrow 2010</a>). Women who have experienced GDM are at a greater risk of metabolic dysfunction in later life (<a href="./references#CD011967-bbs2-0095" title="ShahBR , RetnakaranR , BoothGL . Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care2008;31(8):1668‐9. ">Shah 2008</a>; <a href="./references#CD011967-bbs2-0100" title="VohrBR , BoneyCM . Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome?. Journal of Maternal‐Fetal Medicine2008;21(3):149‐57. ">Vohr 2008</a>), with a crude cumulative incidence of type 2 diabetes of 10% to 20% within 10 years (<a href="./references#CD011967-bbs2-0026" title="BellamyL , CasasJP , HingoraniAD , WilliamsD . Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta‐analysis. Lancet2009;373(9677):1173‐9. ">Bellamy 2009</a>; <a href="./references#CD011967-bbs2-0067" title="KimC , NewtonKM , KnoppRH . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care2002;25:1862‐8. ">Kim 2002</a>), but up to 50% when adjusted for retention and length of follow‐up (<a href="./references#CD011967-bbs2-0067" title="KimC , NewtonKM , KnoppRH . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care2002;25:1862‐8. ">Kim 2002</a>). </p> </section> <section id="CD011967-sec-0042"> <h4 class="title">Neonatal, infant and later outcomes related to gestational diabetes</h4> <p>A significant adverse health outcome for babies born to mothers with GDM is being born LGA or macrosomic (<a href="./references#CD011967-bbs2-0033" title="CatalanoPMA , Huston‐PresleyTL , AminiSB . Increased fetal adiposity: a very sensitive marker of abnormal in utero development. American Journal of Obstetrics &amp; Gynecology2003;189(6):1698‐704. ">Catalano 2003</a>; <a href="./references#CD011967-bbs2-0039" title="CrowtherCA , HillerJE , MossJR , McPheeAJ , JeffriesWS , RobinsonJS , et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England Journal of Medicine2005;352(24):2477‐86. ">Crowther 2005</a>; <a href="./references#CD011967-bbs2-0071" title="LandonMB , SpongCY , ThomE , CarpenterMW , RaminSM , CaseyB , et al. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine2009;361(14):1339‐48. ">Landon 2009</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>; <a href="./references#CD011967-bbs2-0090" title="ReeceEA , LeguizamonG , WiznitzerA . Gestational diabetes: the need for a common ground. Lancet2009;373(9677):1789‐97. ">Reece 2009</a>). Large‐for‐gestational age or macrosomic infants are at increased risk of birth injury, such as shoulder dystocia, perinatal asphyxia, bone fractures and nerve palsies (<a href="./references#CD011967-bbs2-0047" title="EsakoffTF , ChengYW , SparksTN , CaugheyAB . The association between birthweight 4000g or greater and perinatal outcomes in patients with and without gestational diabetes mellitus. American Journal of Obstetrics and Gynecology2009;200(6):672.e1‐672.e4. ">Esakoff 2009</a>; <a href="./references#CD011967-bbs2-0055" title="HenriksenT . The macrosomic fetus: a challenge in current obstetrics. Acta Obstetricia et Gynecologica Scandinavica2008;87(2):134‐45. ">Henriksen 2008</a>; <a href="./references#CD011967-bbs2-0073" title="LangerO , YogevY , MostO , XenakisEM . Gestational diabetes: the consequences of not treating. American Journal of Obstetrics and Gynecology2005;192(4):989‐97. ">Langer 2005</a>; <a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>). </p> <p>Babies born to women with GDM, compared with babies born to women without GDM, have significantly greater skinfold measures and fat mass compared with infants of women with normal glucose tolerance (<a href="./references#CD011967-bbs2-0033" title="CatalanoPMA , Huston‐PresleyTL , AminiSB . Increased fetal adiposity: a very sensitive marker of abnormal in utero development. American Journal of Obstetrics &amp; Gynecology2003;189(6):1698‐704. ">Catalano 2003</a>). The offspring of women with GDM are heavier (adjusted for height) and have greater adiposity than the offspring of women with normal glycaemia during pregnancy (<a href="./references#CD011967-bbs2-0086" title="PettittDJ , BennettPH , KnowlerWC , BairdHR , AleckKA . Gestational diabetes mellitus and impaired glucose tolerance during pregnancy. Long‐term effects on obesity and glucose tolerance in the offspring. Diabetes1985;34(Suppl 2):119‐22. ">Pettitt 1985</a>; <a href="./references#CD011967-bbs2-0087" title="PettittDJ , NelsonRG , SaadMF , BennettPH , KnowlerWC . Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care1993;16(1):310‐4. ">Pettitt 1993</a>), and are more likely to develop early overweight or obesity, type 2 diabetes (<a href="./references#CD011967-bbs2-0059" title="HillierTA , PedulaKL , SchmidtMM , MullenJA , CharlesMA , PettittDJ . Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. Diabetes Care2007;30(9):2287‐92. ">Hillier 2007</a>; <a href="./references#CD011967-bbs2-0087" title="PettittDJ , NelsonRG , SaadMF , BennettPH , KnowlerWC . Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care1993;16(1):310‐4. ">Pettitt 1993</a>; <a href="./references#CD011967-bbs2-0101" title="WhincupPH , KayeSJ , OwenCG , HuxleyR , CookDG , AnazawaS , et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA2008;300(24):2886‐97. ">Whincup 2008</a>), or metabolic syndrome (a cluster of risk factors defined by the occurrence of three of the following: obesity, hypertension, hypertriglyceridaemia and low concentration of high‐density lipoprotein (HDL) cholesterol) in childhood, adolescence or adulthood (<a href="./references#CD011967-bbs2-0051" title="Guerrero‐RomeroF , Aradillas‐GarcíaC , Simental‐MendiaLE , Monreal‐EscalanteE , de laCruz MendozaE , Rodríguez‐MoranM . Birth weight, family history of diabetes, and metabolic syndrome in children and adolescents. Journal of Pediatrics2010;156(5):719‐23. ">Guerrero‐Romero 2010</a>; <a href="./references#CD011967-bbs2-0053" title="HarderT , RoepkeK , DillerN , StechlingY , DudenhausenJW , PlagemannA . Birth weight, early weight gain, and subsequent risk of type 1 diabetes: systematic review and meta‐analysis. American Journal of Epidemiology2009;169(12):1428‐36. ">Harder 2009</a>). </p> <p>The development of the metabolic syndrome during childhood is a risk factor for the development of adult type 2 diabetes at 25 to 30 years of age (<a href="./references#CD011967-bbs2-0078" title="MorrisonJA , FriedmanLA , WangP , GlueckCJ . Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. Journal of Pediatrics2008;152(2):201‐6. ">Morrison 2008</a>). These health problems repeat across generations (<a href="./references#CD011967-bbs2-0042" title="DabeleaD , Snell‐BergeonJK , HartsfieldCL , BischoffKJ , HammanRF , McDuffieRS , et al. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care2005;28(3):579‐84. ">Dabelea 2005</a>; <a href="./references#CD011967-bbs2-0079" title="MullaWR , HenryTQ , HomkoCJ . Gestational diabetes screening after HAPO: has anything changed?. Current Diabetes Reports2010;10(3):224‐8. ">Mulla 2010</a>) and are important from a public health perspective, because with each generation the prevalence of diabetes increases. Other adverse outcomes which are increased for babies born to women with GDM include respiratory distress syndrome, hypoglycaemia (which if prolonged can cause brain injury), hyperbilirubinaemia, hypertrophic cardiomyopathy, hypocalcaemia, hypomagnesaemia, polycythaemia and admission to the neonatal nursery (<a href="./references#CD011967-bbs2-0075" title="Metzger B for The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine2008;358:1991‐2002. ">Metzger 2008</a>; <a href="./references#CD011967-bbs2-0090" title="ReeceEA , LeguizamonG , WiznitzerA . Gestational diabetes: the need for a common ground. Lancet2009;373(9677):1789‐97. ">Reece 2009</a>). </p> </section> </section> <section id="CD011967-sec-0043"> <h3 class="title" id="CD011967-sec-0043">Description of the intervention</h3> <p>First‐line treatment for women with GDM is usually a lifestyle intervention combining dietary and exercise components. Where glycaemic treatment targets are not attained by lifestyle interventions alone, or where initial glucose levels are considered to be very high, the option for treatment is to introduce a pharmacological intervention. Current options include subcutaneous insulin or oral anti‐diabetic pharmacological therapies. </p> <p>There has been an increase in the use of oral anti‐diabetic pharmacological therapies as an alternative to subcutaneous insulin (<a href="./references#CD011967-bbs2-0083" title="OgunyemiDA , FongA , RadS , KjosSL . Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Study group (IADPSG). Diabetes Medicine2011;28(8):976‐86. ">Ogunyemi 2011</a>) for the treatment of women with GDM, due to lower costs, ease of administration and acceptability (<a href="./references#CD011967-bbs2-0093" title="RyuRJ , HaysKE , HebertMF . Gestational diabetes mellitus management with oral hypoglycemic agents. Seminars in Perinatology2014;38(8):508‐15. ">Ryu 2014</a>). The most commonly used therapies are glyburide (glibenclamide) and metformin, although there are other less frequently used anti‐diabetic pharmacological therapies such as acarbose (<a href="./references#CD011967-bbs2-0065" title="KalraB , GuptaY , SinglaR , KlaraS . Use of oral anti‐diabetic agents in pregnancy: a pragmatic approach. North American Journal of Medicine &amp; Science2015;7(1):6‐12. ">Kalra 2015</a>). Despite their wide use, oral antidiabetic pharmacological therapies are not licensed for use during pregnancy in many countries (including Australia, New Zealand, UK, USA). </p> <section id="CD011967-sec-0044"> <h4 class="title">First generation sulphonylureas</h4> <p>First generation sulphonylureas, such as chlorpropamide and tolbutamide have been used to treat diabetes in pregnancy in the past. Both drugs cross the placenta and have been associated with prolonged neonatal hypoglycaemia (<a href="./references#CD011967-bbs2-0036" title="ChristesenH , MelenderA . Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. European Journal of Endocrinology1998;138(6):698‐701. ">Christesen 1998</a>; <a href="./references#CD011967-bbs2-0066" title="KemballML , McIverC , MilnerRDG , NourseCH , SchiffD , TiernanJR . Neonatal hypoglycaemia in infants of diabetic mothers given sulphonyureas drugs in pregnancy. Archives of Disease in Childhood1970;45(243):696‐701. ">Kemball 1970</a>). </p> </section> <section id="CD011967-sec-0045"> <h4 class="title">Second generation sulphonylureas</h4> <p>Second generation sulphonylureas, such as glibenclamide (glyburide) or glipizide work by enhancing insulin secretion. In pregnancy, studies have focused on the use of glibenclamide as it was shown to have the least placental passage in vitro (<a href="./references#CD011967-bbs2-0046" title="ElliottBD , LangerO , SchenkerS , JohnsonRF . Insignificant transfer of glyburide occurs across the human placenta. American Journal of Obstetrics and Gynecology1991;165(4 Pt 1):807‐12. ">Elliott 1991</a>). However, with improved assays it is now estimated that cord plasma concentrations of glibenclamide can be 70% to 77% of maternal levels (<a href="./references#CD011967-bbs2-0094" title="SchwarzR , RosennB , AleksaK , KorenG . Transplacental transfer of glyburide; is it clinically significant?. American Journal of Obstetrics and Gynecology2013;208(Suppl 1):S25. ">Schwarz 2013</a>). Glibenclamide is completely metabolised by the liver and the metabolites are excreted equally in bile and urine. Oral tablets are administered at a typical dose of 2.5 to 5 mg taken once a day. Dosage can be increased if glycaemic control is not achieved in increments of 2.5 mg daily at intervals of every seven days (<a href="./references#CD011967-bbs2-0029" title="BrayfeldA (editor) . Martindale: The Complete Drug Reference. London: Pharmaceutical Press, 2014. ">Brayfield 2014</a>). The maximum daily dose is usually 15 mg taken in divided doses. Glibenclamide is associated with weight gain during pregnancy and postpartum and maternal hypoglycaemia (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). Other commonly reported side effects include nausea, vomiting, sensations of fullness, abdominal pain, anorexia, heartburn and diarrhoea. Less common side effects include abnormal liver function, haematological reactions and dermatological reactions (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). Glibenclamide is contraindicated in cases of renal and hepatic insufficiency (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). <a href="./references#CD011967-bbs2-0072" title="LangerO , ConwayD , BerkusM , XenakisE‐J , GonzalesO . A comparison of glyburide and insulin in women with gestational diabetes mellitus. New England Journal of Medicine2000;343(16):1134‐8. ">Langer 2000</a> reported equivalence between glyburide and subcutaneous insulin for the primary outcome of glycaemic control and reported that glibenclamide was not detected in the cord blood of any of the babies whose mother had been treated with glibenclamide in their trial. </p> </section> <section id="CD011967-sec-0046"> <h4 class="title">Metformin</h4> <p>Metformin is a biguanide that can be administered in immediate‐release or sustained‐release oral preparations. The drug is absorbed along the entire gastrointestinal mucosa, but absorption is incomplete. Typical doses and dose scheduling of metformin provide steady‐state plasma concentrations within 24 to 48 hours of administration and are generally less than 1 microgram/mL. Metformin is excreted unchanged in the urine and is not metabolised by the liver. Tablets should be taken in divided doses with meals. The initial dose is typically 500 mg taken once or twice daily and may be increased over subsequent weeks, dependent on glycaemic control, up to a maximum of 1000 mg three times per day (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). In clinical trials using metformin during pregnancy the maximum dose is 2500 mg daily (<a href="./references#CD011967-bbs2-0092" title="RowanJA , HagueWM , GaoW , BattinMR , MooreMP , for the MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. New England Journal of Medicine2008;358(19):2003‐15. ">Rowan 2008</a>). Renal insufficiency is reported as a contra‐indication to the prescription of metformin (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>). </p> <p>Metformin is known to cross the placenta although there is no evidence to suggest that this leads to fetal abnormalities (<a href="./references#CD011967-bbs2-0045" title="EkpebeghCO , CoetzeeEJ , Van derMerweL , LevettNS . A 10‐year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose‐lowering agents. Diabetic Medicine2007;24(3):253‐8. ">Ekpebegh 2007</a>; <a href="./references#CD011967-bbs2-0050" title="GilbertC , ValoisM , KorenG . Pregnancy outcome after first‐trimester exposure to metformin: a meta‐analysis. Fertility and Sterility2006;86(3):658‐63. ">Gilbert 2006</a>). Maternal lactic acidosis is a rare (0.03 cases per 1000 patient years) but is a serious metabolic condition that is associated with accumulation of metformin during treatment (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). Metformin is commonly associated with gastrointestinal disturbances (diarrhoea, nausea, vomiting) (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). Mild erythema, reduced vitamin B12 absorption and a metallic taste are also reported as side effects of metformin (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). As very little metformin is transferred to human breast milk it is thought to be safe during breastfeeding (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). A sentinel trial conducted by <a href="./references#CD011967-bbs2-0092" title="RowanJA , HagueWM , GaoW , BattinMR , MooreMP , for the MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. New England Journal of Medicine2008;358(19):2003‐15. ">Rowan 2008</a> reported equivalence between metformin and subcutaneous insulin for maternal and infant outcomes. </p> </section> <section id="CD011967-sec-0047"> <h4 class="title">Combined metformin and glibenclamide</h4> <p>Metformin and glibenclamide are available in some regions in a combined formulation (Europe, USA). </p> </section> <section id="CD011967-sec-0048"> <h4 class="title">Acarbose</h4> <p>Acarbose is an alpha‐glucosidase inhibitor that delays the digestion of carbohydrates, thus resulting in a reduced increase in post‐prandial blood glucose concentrations (<a href="http://www.accessdata.fda.gov/scripts/cder/daf" target="_blank">www.accessdata.fda.gov/scripts/cder/daf/</a>). The typical initial dose is 75 to 150 mg taken in three divided doses. This can be further increased to a maximum of 600 mg per day (in divided doses) after four to eight weeks. Acarbose is metabolised within the gastrointestinal tract and the small amount that is excreted is via the urine (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>; <a href="http://www.accessdata.fda.gov/scripts/cder/daf" target="_blank">www.accessdata.fda.gov/scripts/cder/daf/</a>). Animal studies have not found an association between acarbose and fetal teratogenicity, but data are lacking in human studies (<a href="./references#CD011967-bbs2-0065" title="KalraB , GuptaY , SinglaR , KlaraS . Use of oral anti‐diabetic agents in pregnancy: a pragmatic approach. North American Journal of Medicine &amp; Science2015;7(1):6‐12. ">Kalra 2015</a>). Acarbose is not associated with maternal hypoglycaemia but is frequently associated with gastrointestinal side effects (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). Acarbose is contraindicated in people with inflammatory bowel disease or similar conditions, malabsorption syndromes, severe hepatic or renal impairment (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). </p> </section> <section id="CD011967-sec-0049"> <h4 class="title">Oral insulin</h4> <p>Oral insulin is currently under research development for the treatment of diabetes mellitus, which may include GDM (<a href="./references#CD011967-bbs2-0049" title="FonteP , AraujoF , ReisS , SarmentoB . Oral insulin delivery: how far are we?. Journal of Diabetes Science and Technology2013;7(2):520‐31. ">Fonte 2013</a>; <a href="./references#CD011967-bbs2-0062" title="IyerH , KhedkarA , VermaM . Oral insulin ‐ a review of current status. Obesity and Metabolism2010;12(3):179‐85. ">Iyer 2010</a>). This systematic review will not include trials of oral insulin as they will be included in the review of <i>Insulin for the treatment of women with gestational diabetes</i> (<a href="./references#CD011967-bbs2-0031" title="BrownJ , GrzeskowiakL , WilliamsonK , DownieMR , CrowtherCA . Insulin for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD012037] ">Brown 2016</a>). </p> </section> </section> <section id="CD011967-sec-0050"> <h3 class="title" id="CD011967-sec-0050">How the intervention might work</h3> <section id="CD011967-sec-0051"> <h4 class="title">Glibenclamide</h4> <p>Glibenclamide stimulates increased insulin secretion by binding to pancreatic beta‐cell receptors. There is reduced basal hepatic glucose production and enhancement of peripheral insulin action at post‐receptor (probably intracellular) sites. The mechanism of action of glibenclamide requires functional beta‐cells (<a href="./references#CD011967-bbs2-0084" title="PataneG , PiroS , AnelloM , Rabuazzo , VigneriR , PurrelloF . Exposure to glibenclamide increases rat beta cells sensitivity to glucose. British Journal of Pharmacology2000;129:887‐92. ">Patanè 2000</a>). Glibenclamide also inhibits glucagon‐producing alpha cells in the pancreas and increases the release of somatostatin. There is a mild diuretic action which increases free water clearance (<a href="./references#CD011967-bbs2-0088" title="RadóJP , BorbélyL , SzendeL , FischerJ , TakóJ . Investigation of the diuretic effect of glibenclamide in healthy subjects and in patients with pituitary and nephrogenic diabetes insipidus. Hormone and Metabolic Research1974;6(4):289‐92. ">Radó 1974</a>). </p> </section> <section id="CD011967-sec-0052"> <h4 class="title">Metformin</h4> <p>Metformin actions are not completely understood but it inhibits glucogenesis in the liver, delays glucose absorption from the gastrointestinal tract and stimulates glucose uptake into the peripheral tissues. It has been suggested that as metformin increases insulin sensitivity, it does not stimulate insulin release, but does require the presence of insulin to potentiate its antihyperglycaemic effect. Both fasting and post‐prandial blood glucose are lowered in individuals with diabetes. As metformin does not stimulate insulin secretion it is not associated with an increase in hypoglycaemia in diabetic or non‐diabetic populations (<a href="http://www.medsafe.govt.nz" target="_blank">www.medsafe.govt.nz</a>). Metformin may protect β‐cell function in the baby/child/adult and as a consequence reduce the cross generational effects of obesity and type 2 diabetes (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). During pregnancy the pharmacological action of metformin is altered slightly due to enhanced renal elimination, varying food absorption and gastrointestinal transit times (<a href="./references#CD011967-bbs2-0096" title="SimmonsD . Safety considerations with pharmacological treatment of gestational diabetes mellitus. Drug Safety2015;38(1):65‐78. [DOI: 10.1007/s40264‐014‐0253‐9] ">Simmons 2015</a>). </p> </section> <section id="CD011967-sec-0053"> <h4 class="title">Acarbose</h4> <p>Acarbose does not enhance insulin secretion. It reduces intestinal carbohydrate absorption by inhibiting the cleavage of disaccharides and oligosaccharides to monosaccharides in the small intestine resulting in reduced glucose absorption and lower post‐prandial glucose concentrations (<a href="./references#CD011967-bbs2-0065" title="KalraB , GuptaY , SinglaR , KlaraS . Use of oral anti‐diabetic agents in pregnancy: a pragmatic approach. North American Journal of Medicine &amp; Science2015;7(1):6‐12. ">Kalra 2015</a>). </p> </section> </section> <section id="CD011967-sec-0054"> <h3 class="title" id="CD011967-sec-0054">Why it is important to do this review</h3> <p>Although oral anti‐diabetic pharmacological therapies are more acceptable to women with GDM (<a href="./references#CD011967-bbs2-0092" title="RowanJA , HagueWM , GaoW , BattinMR , MooreMP , for the MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. New England Journal of Medicine2008;358(19):2003‐15. ">Rowan 2008</a>), cost less and are easier to administer than subcutaneous insulin, the safety of these therapies is still unclear. </p> <p>The comparison of subcutaneous or oral insulin with oral anti‐diabetic pharmacological therapies is the subject of a new Cochrane Review and will not therefore be covered in this review. </p> <p>The superiority of one anti‐diabetic pharmacological therapy over another has not previously been addressed by a Cochrane systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011967-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-sec-0055">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-sec-0277">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011967-sec-0055"></div> <p>To evaluate the effects of oral anti‐diabetic pharmacological therapies for treating women with GDM. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011967-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-sec-0056">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-sec-0278">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011967-sec-0056"></div> <section id="CD011967-sec-0057"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011967-sec-0058"> <h4 class="title">Types of studies</h4> <p>We included published or unpublished randomised, quasi‐randomised or cluster‐randomised trials in full text or abstract format. We excluded cross‐over trials. Conference abstracts were handled in the same way as full publications. </p> </section> <section id="CD011967-sec-0059"> <h4 class="title">Types of participants</h4> <p>Participants were pregnant women diagnosed with gestational diabetes mellitus (GDM) (diagnosis as defined by the individual trial). Women with type 1 or type 2 diabetes diagnosed prior to pregnancy were excluded. </p> </section> <section id="CD011967-sec-0060"> <h4 class="title">Types of interventions</h4> <p>We included those anti‐diabetic pharmacological therapies that were used during pregnancy including metformin, glibenclamide, acarbose, tolbutamide, chlorpropamide or any combination of these therapies. Only oral anti‐diabetic pharmacological therapies were included in this review. We will include any new therapies prescribed for the treatment of women with GDM in updates of the review. </p> <p> <ul id="CD011967-list-0002"> <li> <p>Oral anti‐diabetic pharmacological therapy versus placebo or no pharmacological treatment.</p> </li> <li> <p>A single oral anti‐diabetic pharmacological therapy versus an alternative oral anti‐diabetic pharmacological therapy (drug A versus drug B). </p> </li> <li> <p>Any combination of oral anti‐diabetic pharmacological therapies versus any combination of oral anti‐diabetic pharmacological therapies (drug A followed by drug B versus drug B followed by drug A for example). </p> </li> <li> <p>Oral anti‐diabetic pharmacological therapy versus another intervention (excluding insulin) not specified above. </p> </li> </ul> </p> <p>We have not included the comparison of oral anti‐diabetic pharmacological therapies versus insulin in this review as it will be covered in the review entitled <i>Insulin for the treatment of women with gestational diabetes</i> (<a href="./references#CD011967-bbs2-0031" title="BrownJ , GrzeskowiakL , WilliamsonK , DownieMR , CrowtherCA . Insulin for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD012037] ">Brown 2016</a>). </p> </section> <section id="CD011967-sec-0061"> <h4 class="title">Types of outcome measures</h4> <section id="CD011967-sec-0062"> <h5 class="title">Primary outcomes</h5> <section id="CD011967-sec-0063"> <h6 class="title">Maternal</h6> <p> <ul id="CD011967-list-0003"> <li> <p>Hypertensive disorders of pregnancy (including pre‐eclampsia, pregnancy‐induced hypertension, eclampsia as defined by trialists) </p> </li> <li> <p>Caesarean section</p> </li> <li> <p>Development of type 2 diabetes</p> </li> </ul> </p> </section> <section id="CD011967-sec-0064"> <h6 class="title">Neonatal</h6> <p> <ul id="CD011967-list-0004"> <li> <p>Perinatal (fetal and neonatal death) and later infant mortality</p> </li> <li> <p>Large‐for‐gestational age (LGA) (as defined by trialists)</p> </li> <li> <p>Death or serious morbidity composite (variously defined by trials, e.g. perinatal or infant death, shoulder dystocia, bone fracture or nerve palsy) </p> </li> <li> <p>Neurosensory disability in later childhood (as defined by trialists)</p> </li> </ul> </p> </section> </section> <section id="CD011967-sec-0065"> <h5 class="title">Secondary outcomes</h5> <section id="CD011967-sec-0066"> <h6 class="title">Maternal</h6> <p> <ul id="CD011967-list-0005"> <li> <p>Use of additional pharmacotherapy</p> </li> <li> <p>Maternal hypoglycaemia (as defined by trialists)</p> </li> <li> <p>Glycaemic control during/end of treatment (as defined by trialists)</p> </li> <li> <p>Weight gain in pregnancy</p> </li> <li> <p>Adherence to the intervention</p> </li> <li> <p>Induction of labour</p> </li> <li> <p>Placental abruption</p> </li> <li> <p>Postpartum haemorrhage (as defined by trialists)</p> </li> <li> <p>Postpartum infection</p> </li> <li> <p>Perineal trauma/tearing</p> </li> <li> <p>Breastfeeding at discharge, six weeks postpartum, six months or longer</p> </li> <li> <p>Maternal mortality</p> </li> <li> <p>Sense of well‐being and quality of life</p> </li> <li> <p>Behavioural changes associated with the intervention</p> </li> <li> <p>Views of the intervention</p> </li> <li> <p>Relevant biomarker changes associated with the intervention (including adiponectin, free fatty acids, triglycerides, high‐density lipoproteins, low‐density lipoproteins, insulin) </p> </li> </ul> </p> </section> <section id="CD011967-sec-0067"> <h6 class="title">Long‐term outcomes for mother</h6> <p> <ul id="CD011967-list-0006"> <li> <p>Postnatal depression</p> </li> <li> <p>Body mass index (BMI)</p> </li> <li> <p>Postnatal weight retention or return to pre‐pregnancy weight</p> </li> <li> <p>Type 1 diabetes</p> </li> <li> <p>Type 2 diabetes</p> </li> <li> <p>Impaired glucose tolerance</p> </li> <li> <p>Subsequent gestational diabetes</p> </li> <li> <p>Cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome) </p> </li> </ul> </p> </section> <section id="CD011967-sec-0068"> <h6 class="title">Fetal/neonatal outcomes</h6> <p> <ul id="CD011967-list-0007"> <li> <p>Stillbirth</p> </li> <li> <p>Neonatal death</p> </li> <li> <p>Macrosomia (greater than 4000 g; or as defined by individual study)</p> </li> <li> <p>Small‐for‐gestational age (as defined by trialists)</p> </li> <li> <p>Birth trauma (shoulder dystocia, bone fracture, nerve palsy)</p> </li> <li> <p>Gestational age at birth</p> </li> <li> <p>Preterm birth (less than 37 weeks’ gestation; and less than 32 weeks' gestation)</p> </li> <li> <p>Five‐minute Apgar less than seven</p> </li> <li> <p>Birthweight and z score</p> </li> <li> <p>Head circumference and z score</p> </li> <li> <p>Length and z score</p> </li> <li> <p>Ponderal index</p> </li> <li> <p>Adiposity (including skinfold thickness measurements (mm), fat mass)</p> </li> <li> <p>Neonatal hypoglycaemia (as defined by trialists)</p> </li> <li> <p>Respiratory distress syndrome</p> </li> <li> <p>Neonatal jaundice (hyperbilirubinaemia) (as defined by trialists)</p> </li> <li> <p>Hypocalcaemia (as defined by trialists)</p> </li> <li> <p>Polycythaemia (as defined by trialists)</p> </li> <li> <p>Relevant biomarker changes associated with the intervention (including insulin, cord c‐peptide) </p> </li> </ul> </p> </section> <section id="CD011967-sec-0069"> <h6 class="title">Later Infant/childhood outcomes</h6> <p> <ul id="CD011967-list-0008"> <li> <p>Weight and z scores</p> </li> <li> <p>Height and z scores</p> </li> <li> <p>Head circumference and z scores</p> </li> <li> <p>Adiposity (including BMI, skinfold thickness, fat mass)</p> </li> <li> <p>Educational attainment</p> </li> <li> <p>Blood pressure</p> </li> <li> <p>Type 1 diabetes</p> </li> <li> <p>Type 2 diabetes</p> </li> <li> <p>Impaired glucose tolerance</p> </li> <li> <p>Dyslipidaemia or metabolic syndrome</p> </li> </ul> </p> </section> <section id="CD011967-sec-0070"> <h6 class="title">Child as an adult outcomes</h6> <p> <ul id="CD011967-list-0009"> <li> <p>Weight</p> </li> <li> <p>Height</p> </li> <li> <p>Adiposity (including BMI, skinfold thickness, fat mass)</p> </li> <li> <p>Cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome) </p> </li> <li> <p>Employment, education and social status/achievement</p> </li> <li> <p>Dyslipidaemia or metabolic syndrome</p> </li> <li> <p>Type 1 diabetes</p> </li> <li> <p>Type 2 diabetes</p> </li> <li> <p>Impaired glucose tolerance</p> </li> </ul> </p> </section> <section id="CD011967-sec-0071"> <h6 class="title">Health service use</h6> <p> <ul id="CD011967-list-0010"> <li> <p>Number of antenatal visits or admissions</p> </li> <li> <p>Number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse) </p> </li> <li> <p>Admission to neonatal intensive care unit/nursery</p> </li> <li> <p>Length of antenatal stay</p> </li> <li> <p>Length of postnatal stay (maternal)</p> </li> <li> <p>Length of postnatal stay (baby)</p> </li> <li> <p>Cost of maternal care</p> </li> <li> <p>Cost of offspring care</p> </li> <li> <p>Costs associated with the intervention</p> </li> <li> <p>Costs to families associated with the management provided</p> </li> <li> <p>Cost of dietary monitoring (e.g. diet journals, dietician, nurse visits, etc)</p> </li> <li> <p>Costs to families ‐ change of diet, extra antenatal visits</p> </li> <li> <p>Extra use of healthcare services (consultations, blood glucose monitoring, length and number of antenatal visits) </p> </li> <li> <p>Women’s view of treatment advice</p> </li> <li> <p>Duration of stay in neonatal intensive care unit or special care baby unit</p> </li> <li> <p>Duration of maternal and neonatal hospital stay (antenatal, neonatal, postnatal)</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011967-sec-0072"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD011967-sec-0073"> <h4 class="title">Electronic searches</h4> <p>We searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (16 May 2016). </p> <p>The Register is a database containing over 22,000 reports of controlled trials in the field of pregnancy and childbirth. For full search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this link to the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth</a> in the Cochrane Library and select the ‘<i><b>Specialized Register</b> </i> ’ section from the options on the left side of the screen. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD011967-list-0011"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD011967-bbs1-0001" title="">Included studies</a>; <a href="./references#CD011967-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD011967-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD011967-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (14 May 2016). The search terms we used are given in <a href="./appendices#CD011967-sec-0243">Appendix 1</a>. </p> </section> <section id="CD011967-sec-0074"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies. We did not apply any language or date restrictions. </p> </section> </section> <section id="CD011967-sec-0075"> <h3 class="title" id="CD011967-sec-0075">Data collection and analysis</h3> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD011967-sec-0076"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed for inclusion all the potential studies we identified as a result of the search strategy. We resolved any disagreements through discussion. A third person was not required. </p> <p>We created a study flow diagram to map out the number of records identified, included and excluded (<a href="#CD011967-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011967-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011967-sec-0077"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion. Consultation with a third person was not required. We entered data into Review Manager (RevMan) software (<a href="./references#CD011967-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and checked for accuracy. When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD011967-sec-0078"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD011967-bbs2-0057" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We resolved any disagreement by discussion. Consultation with a third person was not required. </p> <section id="CD011967-sec-0079"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD011967-list-0012"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0080"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and will assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011967-list-0013"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0081"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judge that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011967-list-0014"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0082"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD011967-list-0015"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0083"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. No additional data that could be included in a meta‐analysis were supplied by study authors. In future updates, where sufficient information is reported, or can be supplied by the study authors, we will re‐include missing data in the analyses which we undertake. </p> <p>We assessed methods as:</p> <p> <ul id="CD011967-list-0016"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0084"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011967-list-0017"> <li> <p>low risk of bias (where it was clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review were reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes were reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0085"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD011967-list-0018"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD011967-sec-0086"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions<i>(</i><a href="./references#CD011967-bbs2-0057" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses ‐ see <a href="#CD011967-sec-0107">Sensitivity analysis</a>. </p> </section> <section id="CD011967-sec-0087"> <h5 class="title">Assessment of the quality of the evidence using the GRADE approach</h5> <p>We assessed the quality of the evidence using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a> in order to assess the quality of the body of evidence relating to the following outcomes. We selected up to a maximum of seven outcomes for the mother and seven for the infant covering both short‐ and long‐term outcomes for the main comparisons. </p> <section id="CD011967-sec-0088"> <h6 class="title">Maternal outcomes</h6> <p> <ul id="CD011967-list-0019"> <li> <p>Hypertensive disorders of pregnancy (including pre‐eclampsia, pregnancy‐induced hypertension, eclampsia) </p> </li> <li> <p>Caesarean section</p> </li> <li> <p>Development of type 2 diabetes</p> </li> <li> <p>Perineal trauma</p> </li> <li> <p>Return to pre‐pregnancy weight</p> </li> <li> <p>Postnatal depression</p> </li> <li> <p>Induction of labour</p> </li> </ul> </p> </section> <section id="CD011967-sec-0089"> <h6 class="title">Neonatal outcomes</h6> <p> <ul id="CD011967-list-0020"> <li> <p>LGA</p> </li> <li> <p>Perinatal mortality</p> </li> <li> <p>Death or serious morbidity composite (variously defined by studies, e.g. infant death, shoulder dystocia, bone fracture or nerve palsy) </p> </li> <li> <p>Neonatal hypoglycaemia</p> </li> <li> <p>Adiposity</p> </li> <li> <p>Diabetes</p> </li> <li> <p>Neurosensory disability in later childhood</p> </li> </ul> </p> <p>We used the GRADEpro Guideline Development Tool (<a href="http://www.gradepro.org/" target="_blank">GRADEpro GDT</a>) to import data from RevMan (<a href="./references#CD011967-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) in order to create 'Summary of findings' tables. We produced a summary of the intervention effect and a measure of quality for each of the above outcomes using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> </section> <section id="CD011967-sec-0090"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011967-sec-0091"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals (CI). </p> </section> <section id="CD011967-sec-0092"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference (MD) if outcomes were measured in the same way between trials. We used the standardised mean difference (SMD) to combine data from trials that measured the same outcome, but used different methods. </p> </section> </section> <section id="CD011967-sec-0093"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011967-sec-0094"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not identify any cluster‐randomised controlled trials in this version of the systematic review. In future updates, if cluster‐randomised trials are identified, we will include cluster‐randomised trials in the analyses along with individually‐randomised trials. We will make adjustments using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Section 16.3.4 or 16.3.6) using an estimate of the intra‐cluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population (<a href="./references#CD011967-bbs2-0058" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. We will consider it reasonable to combine the results from both cluster‐randomised trials and individually‐randomised trials if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. If cluster‐randomised trials are included, we will seek statistical advice on appropriate analysis to enable inclusion of data in the meta‐analyses. </p> </section> <section id="CD011967-sec-0095"> <h5 class="title">Other unit of analysis issues</h5> <section id="CD011967-sec-0096"> <h6 class="title">Multiple pregnancy</h6> <p>There may be unit of analysis issues that arise when the women randomised have a multiple pregnancy. We did not include any studies including multiple pregnancies in this version of the systematic review. In future updates, if multiple pregnancies are identified, we will present maternal data as per woman randomised and neonatal data per infant. </p> </section> <section id="CD011967-sec-0097"> <h6 class="title">Multiple‐arm studies</h6> <p>Where a trial has multiple intervention arms we planned to avoid 'double counting' of participants by combining groups to create a single pair‐wise comparison if possible. Where this was not possible, we planned to split the 'shared' group into two or more groups with smaller sample size and include two or more (reasonably independent) comparisons. We did not identify any studies of multiple comparisons in this version of the systematic review. </p> </section> </section> </section> <section id="CD011967-sec-0098"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data (more than 20%) in the overall assessment of treatment effect by using sensitivity analysis. However, one of the included studies reported attrition greater than 20% (<a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>) and therefore we did not conduct sensitivity analyses based on attrition in this version of the review. In future updates we plan to explore attrition for sensitivity analysis if sufficient evidence is available. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, that is, we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD011967-sec-0099"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² (<a href="./references#CD011967-bbs2-0056" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 40% and either a Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD011967-sec-0100"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were 10 or more studies in the meta‐analysis, we planned to investigate reporting biases (such as publication bias) using funnel plots. This was not possible in this version of the review. In future updates, where possible, we will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD011967-sec-0101"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD011967-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: that is, where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average of the range of possible treatment effects and we tried to discuss the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. </p> <p>If we used random‐effects analyses, the results were presented as the average treatment effect with 95% CIs, and the estimates of Tau² and I². </p> </section> <section id="CD011967-sec-0102"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we investigated it using subgroup analyses. We considered whether an overall summary was meaningful, and if it was, used random‐effects analysis to produce it. </p> <section id="CD011967-sec-0103"> <h5 class="title">Diagnostic tests used</h5> <p> <ul id="CD011967-list-0021"> <li> <p><a href="./references#CD011967-bbs2-0021" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2013;36(Suppl 1):567‐74. ">ADA 2013</a>, <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a>, <a href="./references#CD011967-bbs2-0080" title="NankervisA , McIntyreHD , MosesR , RossGP , CallawayL , PorterC , et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf(accessed 2014). ">Nankervis 2014</a> versus <a href="./references#CD011967-bbs2-0020" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician‐gynecologists. Obstetrics &amp; Gynecology2013;122(2 Pt 1):406‐16. ">ACOG 2013</a> versus <a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a> versus <a href="./references#CD011967-bbs2-0081" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline 63. London: NICE, 2008. ">NICE 2008</a>; <a href="./references#CD011967-bbs2-0102" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Geneva, Switzerland: WHO, 1999. ">WHO 1999</a>; <a href="./references#CD011967-bbs2-0103" title="World Health Organization. WHO Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Report WHO/NMH/MND/13.2. Geneva, Switzerland: WHO, 2014. ">WHO 2014</a>; <a href="./references#CD011967-bbs2-0060" title="HoffmanL , NolanC , WilsonJD , OatsJJ , Simmons D. The Australasian Diabetes in Pregnancy Society. Gestational diabetes mellitus‐management guidelines. Medical Journal of Australia1998;169(2):93‐7. ">Hoffman 1998</a> versus New Zealand <a href="./references#CD011967-bbs2-0076" title="Ministry of Health. Screening, Diagnosis and Management of Gestational Diabetes in New Zealand: A Clinical Practice Guideline. Wellington: Ministry of Health, 2014. ">Ministry of Health 2014</a> versus other not previously specified. </p> </li> </ul> </p> </section> <section id="CD011967-sec-0104"> <h5 class="title">Timing of diagnosis of GDM</h5> <p> <ul id="CD011967-list-0022"> <li> <p>Early (&lt; 28 weeks' gestation) versus late (≥ 28 weeks' gestation)</p> </li> </ul> </p> <p>There was insufficient data for us to be able to explore subgroup analyses for this review. In future updates, if there is sufficient evidence, we plan to use the following outcomes in subgroup analysis. </p> <section id="CD011967-sec-0105"> <h6 class="title">Maternal outcomes</h6> <p> <ul id="CD011967-list-0023"> <li> <p>Pre‐eclampsia</p> </li> <li> <p>Caesarean section</p> </li> <li> <p>Development of type 2 diabetes</p> </li> </ul> </p> </section> <section id="CD011967-sec-0106"> <h6 class="title">Neonatal outcomes</h6> <p> <ul id="CD011967-list-0024"> <li> <p>LGA</p> </li> <li> <p>Perinatal death or later infant mortality</p> </li> <li> <p>Death or serious morbidity composite (variously defined by trials, e.g. infant death, shoulder dystocia, bone fracture or nerve palsy) </p> </li> <li> <p>Neurosensory disability in later childhood (as defined by trialists).</p> </li> </ul> </p> <p>We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD011967-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We reported the results of subgroup analyses quoting the Chi<sup>2</sup> statistic and P value, and the interaction test I² value. </p> </section> </section> </section> <section id="CD011967-sec-0107"> <h4 class="title">Sensitivity analysis</h4> <p>Where there was evidence of substantial heterogeneity, we explored this by using the quality of the included trials for the primary outcomes. We planned to compare trials that had low risk of bias for allocation concealment with those judged to be of unclear or high risk of bias. We planned to exclude conference abstracts from the meta‐analysis. </p> <p>In future updates, where data are available we plan to investigate the effect of the randomisation unit (i.e. where included cluster‐randomised trials along with individually‐randomised trials). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011967-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011967-sec-0108"></div> <section id="CD011967-sec-0109"> <h3 class="title">Description of studies</h3> <section id="CD011967-sec-0110"> <h4 class="title">Results of the search</h4> <p>We identified 28 potential reports for inclusion in the review (<a href="#CD011967-fig-0001">Figure 1</a>). Eleven studies (20 reports) were included and five studies were excluded. Two studies (<a href="./references#CD011967-bbs2-0017" title="CoinerJ , RoweM , DeVenteJT . The treatment of diabetes in pregnancy; metformin vs glyburide and insulin biomedical evidence of fetopathy. American Journal of Obstetrics and Gynecology2014;210(1 Suppl 1):S148. ">Coiner 2015</a>; <a href="./references#CD011967-bbs2-0018" title="NCT00414245 . Metformin for the treatment of diabetes in pregnancy. clinicaltrials.gov/ct2/show/record/NCT00414245 Date first received: 20 December 2006. ">Sheizaf 2006</a>) are awaiting classification and one study (<a href="./references#CD011967-bbs2-0019" title="NCT02726490 . Glyburide vs Glucovance in the treatment of GDM (GGIG). clinicaltrials.gov/show/NCT02726490 Date first received: 29 March 2016. ">Moore 2016</a>) is ongoing (see <a href="./references#CD011967-sec-0257" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD011967-sec-0258" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD011967-sec-0111"> <h4 class="title">Included studies</h4> <p>Eleven studies (20 reports) were identified that met the inclusion criteria for this review (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). Three of these were published in conference abstract format only (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>). </p> <section id="CD011967-sec-0112"> <h5 class="title">Design</h5> <p>All 11 studies were randomised parallel design.</p> </section> <section id="CD011967-sec-0113"> <h5 class="title">Sample sizes</h5> <p>The 11 studies recruited a total of 1487 women and their babies. Sample size ranged from 40 women reported by <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> to 207 women reported by <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>. </p> </section> <section id="CD011967-sec-0114"> <h5 class="title">Setting</h5> <p>Three studies were conducted in Brazil (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) and USA (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). Two studies were conducted in India (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>). One study each was conducted in South Africa (<a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>), UK (<a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>) and Israel (<a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>). </p> </section> <section id="CD011967-sec-0115"> <h5 class="title">Participants</h5> <p>Maternal age was reported in six of the 11 studies (<a href="#CD011967-tbl-0008">Table 2</a>), maternal body mass index (BMI) (kg/m<sup>2</sup>) was reported in five of 11 studies (<a href="#CD011967-tbl-0009">Table 3</a>) and gestational age at study entry was reported in four of 11 studies (<a href="#CD011967-tbl-0010">Table 4</a>). </p> <div class="table" id="CD011967-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean maternal age (years) ± SD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 4.5 (n = 24), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5 ± 5.8 (n = 19), acarbose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3 ± 6, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 6, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.4 ± 4.4 (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.6 ± 4.6 (n = 80), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 ± 7.1 (n = 75) ‐ metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.6 ± 7.8 (n = 74), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, standard care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlopropramide 30.9 (n = 58)</p> <p>Tolbutamide 29.7 (n = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diet 32.7 (n = 56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6 ± 5.6 (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3 ± 5.4 (n = 96), glibenclamide</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011967-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Maternal BMI kg/m2 </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Timepoint BMI measured at</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.5 ± 5.8 (n = 24), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.7 ± 4.2 (n = 19), acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.0 ± 4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.9 ± 5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐pregnancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 4.4 (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.8 ± 4.0 (n = 80), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.8 ± 5.8 (n = 75), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.7 ± 7.0 (n = 74), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 5.4 (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 ± 5.9 (n = 96), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011967-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Gestational age at trial entry</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.0 ± 2.0, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.0 ± 1.0, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.3 ± 3.3 weeks' (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.7 ± 3.7 weeks' (n = 80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3 ± 6.8 weeks' (n = 75), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.1 ± 5.0 weeks' (n = 74), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.0 ± 6.4 weeks' (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.4 ± 7.1 weeks' (n = 96), glibenclamide</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011967-sec-0116"> <h5 class="title">Interventions and comparisons</h5> <p>Four different comparisons were reported.</p> <section id="CD011967-sec-0117"> <h6 class="title">Oral anti‐diabetic pharmacological therapy versus placebo or usual care</h6> <p>One study compared glibenclamide with placebo (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>); one study compared acarbose with placebo (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>), one study compared metformin with standard care (<a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>) and one study compared tolbutamide and chlorpropamide with diet (<a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>). </p> </section> <section id="CD011967-sec-0118"> <h6 class="title">Metformin versus glibenclamide</h6> <p>Five studies compared metformin with glibenclamide (<a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). </p> </section> <section id="CD011967-sec-0119"> <h6 class="title">Glibenclamide versus acarbose</h6> <p>One study compared glibenclamide with acarbose (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>). </p> </section> <section id="CD011967-sec-0120"> <h6 class="title">Glibenclamide with or without metformin versus metformin with or without glibenclamide</h6> <p>One study compared glibenclamide plus metformin if glycaemic targets were not met, with metformin plus glibenclamide if glycaemic targets were not met (<a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>). </p> </section> </section> <section id="CD011967-sec-0121"> <h5 class="title">Diagnostic criteria</h5> <p>Four different diagnostic criteria were used by the eight studies that reported this.</p> <p> <ul id="CD011967-list-0025"> <li> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> and <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> used the National Diabetes Data Group (NDGG 1979) </p> </li> <li> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> and <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> used WHO (1999) criteria </p> </li> <li> <p>Three studies (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>) used Carpenter and Coustan criteria </p> </li> <li> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> used WHO criteria but the abstract did not state if this was 1999 or 2015 criteria </p> </li> <li> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>, <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> and <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> did not state which diagnostic criteria they used </p> </li> </ul> </p> <p>Refer to <a href="#CD011967-tbl-0007">Table 1</a> and <a href="#CD011967-tbl-0011">Table 5</a>. </p> <div class="table" id="CD011967-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnostic criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Screening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐28 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour, 50 g OGCT(≥ 7.8 mmol/L; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>3 hour, 100 g OGTT</p> <p>Fasting &lt; 5.8 mmol/L (105 mg/dL)</p> <p>1‐hour ≥ 10.6 mmol/L (190 mg/dL)</p> <p>2‐hour ≥ 9.2 mmol/L (165 mg/dL)</p> <p>3‐hour ≥ 8.1 mmol/L (145 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Diabetes Data Group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g OGTT</p> <p>Fasting ≥ 6.1 mmol/L (110 mg/dL);</p> <p>2‐hour value ≥ 7.8 mmol/L (140 mg/dL).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria (old)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐34 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria but not stated if 1999 or 2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.8 mmol/L; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>100 g OGTT:</p> <p>fasting glucose ≥ 5.3 mmol/L,</p> <p>1‐hour ≥ 10 mmol/L,</p> <p>2‐hour ≥ 8.6 mmol/L,</p> <p>3‐hour ≥ 7.8 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐28 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>100 g OGTT:</p> <p>fasting glucose ≥ 5.3 mmol/L,</p> <p>1‐hour ≥ 10 mmol/L,</p> <p>2‐hour ≥ 8.6 mmol/L,</p> <p>3‐hour ≥ 7.8 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Diabetes Data Group (1979)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.2 mmol/L; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hour 100 g OGTT using criteria with 2 or more abnormal results.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fasting blood glucose 5.1 to 5.4 mmol/L,</p> <p>2 hour &lt; 8.5 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.2 mmol/L; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hour 100 g OGTT using criteria with 2 or more abnormal results.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria (1999)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>OGCT oral glucose tolerance test; OGTT oral glucose tolerance test</p> </div> </div> </section> <section id="CD011967-sec-0122"> <h5 class="title">Treatment targets</h5> <p>Eight studies reported three different treatment targets for fasting blood glucose (Refer to <a href="#CD011967-tbl-0012">Table 6</a>): </p> <div class="table" id="CD011967-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Treatment target</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fasting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1‐hour post‐prandial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2‐hour post‐prandial</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.0 mmol/L</p> <p>(90 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.5 mmol/L</p> <p>(100 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7.5 mmol/L</p> <p>(135 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7.8 mmol/L</p> <p>(140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.8 mmol/L</p> <p>(105 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 minutes</p> <p>&lt; 7.2 mmol/L</p> <p>(130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3 mmol/L*</p> <p>(150 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 mmol/L</p> <p>(90 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Post‐prandial timing not specified</p> </div> </div> <p> <ul id="CD011967-list-0026"> <li> <p>less than 5.0 mmol/L (90 mg/dL) (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>); </p> </li> <li> <p>less than 5.3 mmol/L (95 mg/dL) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>); </p> </li> <li> <p>less than 5.8 mmol/L (105 mg/dL) (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). </p> </li> </ul> </p> <p>Four studies reported four different treatment targets for one‐hour postprandial blood glucose: </p> <p> <ul id="CD011967-list-0027"> <li> <p>less than 6.7 mmol/L (120 mg/dL) (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>); </p> </li> <li> <p>less than 7.2 mmol/L (130 mg/dL) (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>) 90 minutes; </p> </li> <li> <p>less than 7.5 mmol/L (135 mg/dL) (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>); </p> </li> <li> <p>less than 7.8 mmol/L (140 mg/dL) (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>). </p> </li> </ul> </p> <p>Four studies reported two different treatment targets for two‐hour postprandial blood glucose: </p> <p> <ul id="CD011967-list-0028"> <li> <p>less than 5.5 mmol/L (100 mg/dL) (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>); </p> </li> <li> <p>less than 6.7 mmol/L (120 mg/dL) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). </p> </li> </ul> </p> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> reported "good control" was obtained with a postprandial (timing not specified) blood glucose reading of less than 8.3 mmol/L (150 mg/dL). <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> and <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> did not provide details of glycaemic targets for treatment. </p> <p>The <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> study included women with both GDM and pre‐gestational diabetes. The proportions of women included with each type of diabetes were unclear and therefore the data have not been included in any meta‐analyses. </p> <p>See <a href="./references#CD011967-sec-0255" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD011967-sec-0123"> <h4 class="title">Excluded studies</h4> <p>We excluded five studies. One study comparing metformin and placebo was registered with the clinical studies registry <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> in 2010. Subsequent updates indicate that the study never started recruitment due to insufficient funding for enrolment of participants (<a href="./references#CD011967-bbs2-0014" title="NCT01171456 . Early intervention for gestational diabetes. clinicaltrials.gov/show/NCT01171456 Date first received: 13 July 2010. ">Branch 2010</a>). <a href="./references#CD011967-bbs2-0015" title="NCT01329016 . Glyburide and metformin for gestational diabetes mellitus. clinicaltrials.gov/show/NCT01329016 Date first received: 22 March 2011. ">Hebert 2011</a>, was a pharmacokinetic study and not an interventional study. We excluded <a href="./references#CD011967-bbs2-0012" title="NCT01855763 . Metformin in gestational diabetes and type 2 diabetes in pregnancy in a developing country. clinicaltrials.gov/show/NCT01855763 Date first received: 9 May 2013. ">Ainuddin 2013</a> as the comparison was ineligible for inclusion in this review, the trial compared metformin and insulin. We excluded two studies as the intervention was postpartum (<a href="./references#CD011967-bbs2-0013" title="BerensP , ViteriO , HutchinsonM , BlackwellS , SmithJ , RaminS , et al. The effects of metformin on breastfeeding in women with gestational diabetes compared to placebo. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S340. ">Berens 2015</a>; <a href="./references#CD011967-bbs2-0016" title="SmithJ , SallmanMA , BerensP , ViteriO , HutchinsonM , RaminS , et al. Metformin improved lipid profiles in women with gestational diabetes in the first six weeks postpartum. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S324. ">Smith 2015</a>). See <a href="./references#CD011967-sec-0256" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011967-sec-0124"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to <a href="#CD011967-fig-0002">Figure 2</a>; <a href="#CD011967-fig-0003">Figure 3</a> and <a href="./references#CD011967-sec-0255" title="">Characteristics of included studies</a> for 'risk of bias' summaries of the included studies. </p> <div class="figure" id="CD011967-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD011967-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD011967-sec-0125"> <h4 class="title">Allocation</h4> <p>We judged five of the 11 included studies to be of low risk of bias for random sequence generation as they all used computer‐generated number tables (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). The remaining studies stated that they were randomised but did not provide sufficient details to make a judgement so we therefore considered them to be unclear risk of bias (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>). </p> <p>We considered allocation concealment to be low risk of bias in five studies. <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> reported using "brown envelopes containing outside the randomisation number and in the inside a sheet defining which therapy the patient was allocated to"; <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> reported that masking, allocation and assignment was done by the investigational drug pharmacy; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> used "sequentially labelled opaque envelopes" that were maintained "in a central research office by research officers not involved in patient care". <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> used "sequentially labelled, opaque, sealed envelopes" and <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> used sequential numbering in brown envelopes. <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> reported using "..prefilled sealed envelopes created by independent research midwives within the department". The remaining studies provided no details as to the method of allocation concealment and we judged them to be of unclear risk of bias (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>). </p> </section> <section id="CD011967-sec-0126"> <h4 class="title">Blinding</h4> <section id="CD011967-sec-0127"> <h5 class="title">Performance bias</h5> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> reported that the "subject", "caregiver" and "investigator" were blinded and the study was placebo controlled (we obtained additional information from the study protocol). Sham dose adjustments were made in the placebo group. <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> reported that the physician and the participant were blinded to treatment allocation and that medication was provided from the pharmacy in a sealed envelope. We judged these studies to be low risk of bias. </p> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> reported that the study was double‐blind but gave no details as to who was blinded. We judged the study to be of unclear risk of bias. </p> <p>Six studies reported that they were open label and therefore participants and staff were not blinded to the treatment allocation (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> reported that the women in their study were not blinded to the treatment allocation. We considered these studies to be of high risk of bias. </p> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> did not provide any details regarding blinding and we therefore judged it as being unclear risk of bias. </p> </section> <section id="CD011967-sec-0128"> <h5 class="title">Detection bias</h5> <p>In the trial registration document, <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> reported that the "outcome assessor" was blinded. <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> reported that the neonatologists who cared for the infants after birth were blinded to treatment allocation. We judged these studies to be low risk of bias. </p> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> reported that the study was double‐blind but gave no details as to who was blinded. We judged the study to be of unclear risk of bias. </p> <p>Eight studies reported that they were open label or provided no details relating to blinding of outcome assessors, or both (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). We considered these studies to be of unclear risk of bias. </p> </section> </section> <section id="CD011967-sec-0129"> <h4 class="title">Incomplete outcome data</h4> <p>There was no evidence of risk of attrition bias in six studies (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> reported a 5% (20/395) loss to follow‐up but did not provide any reasons for the attrition. No details of attrition were provided by <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>, although the study stated that analysis was conducted by intention to treat. We judged this study to be of unclear risk of bias. In <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> 8/36 (22%) women dropped out of the metformin arm and 24/45 (55%) dropped out of the glibenclamide arm. We judged this study to be high risk of bias. In the <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> pilot study, three women did not complete the trial and were not analysed, but it is unclear as to which group they were allocated ‐ we assessed this study to be at an unclear risk of bias. </p> </section> <section id="CD011967-sec-0130"> <h4 class="title">Selective reporting</h4> <p>There was no evidence of risk of reporting bias in three studies (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). </p> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> reported additional maternal and neonatal outcomes to those listed a priori in the trial registration document. Three studies were only published in abstract form and or no full publication could be identified (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014)</a>. One study failed to report on an outcome that had been prespecified (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>), two studies reported additional outcomes that were not pre‐specified (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>) and one study did not pre‐specify any outcomes (<a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>). We judged these studies to be of high risk of bias. </p> </section> <section id="CD011967-sec-0131"> <h4 class="title">Other potential sources of bias</h4> <p>There was no evidence of other sources of bias in three studies (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). </p> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> did not provide data for the population demographics and we were unable to judge the risk of bias, which we have allocated an unclear risk. </p> <p>In one study (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>) an interim analysis requested by the local data monitoring committee showed significant differences in outcomes and the study was stopped before the total sample size of 86 women per group was achieved. The intervention and control groups were balanced at baseline although the metformin group had higher fasting triglyceride levels. We judged the study to be of unclear risk of bias. </p> <p>Three studies were reported in abstract form only and there were no baseline demographic data (<a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>). The <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> study remains unpublished. We therefore judged these studies to be of high risk of bias. </p> <p>The <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> study appears to have been registered twice as NCT00942552 and as NCT00744965 with the same outcomes, interventions and sample size. The population was 93% Hispanic and therefore the results may not be generalisable to other ethnicities. We judged the study to be high risk of bias. </p> <p>We could not separate the data from the <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> study for women with GDM and those with pregestational diabetes, and the study did not report the proportions of women for these categories. We did not, therefore, include the data in any meta‐analyses. </p> </section> </section> <section id="CD011967-sec-0132"> <h3 class="title" id="CD011967-sec-0132">Effects of interventions</h3> <p>See: <a href="./full#CD011967-tbl-0001"><b>Summary of findings for the main comparison</b> Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</a>; <a href="./full#CD011967-tbl-0002"><b>Summary of findings 2</b> Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</a>; <a href="./full#CD011967-tbl-0003"><b>Summary of findings 3</b> Metformin versus glibenclamide ‐ maternal outcomes</a>; <a href="./full#CD011967-tbl-0004"><b>Summary of findings 4</b> Metformin versus glibenclamide ‐ neonatal outcomes</a>; <a href="./full#CD011967-tbl-0005"><b>Summary of findings 5</b> Glibenclamide versus acarbose ‐ maternal outcomes</a>; <a href="./full#CD011967-tbl-0006"><b>Summary of findings 6</b> Glibenclamide versus acarbose ‐ neonatal outcomes</a> </p> <section id="CD011967-sec-0133"> <h4 class="title">Oral anti‐diabetic pharmacological therapy versus placebo or standard care (comparison 1) </h4> <p>Three studies reported data for this comparison (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>). <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> compared glibenclamide with placebo and <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> compared acarbose with placebo. <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> compared metformin with standard care. </p> <section id="CD011967-sec-0134"> <h5 class="title">Maternal primary outcomes</h5> <section id="CD011967-sec-0135"> <h6 class="title">1.1 Hypertensive disorders of pregnancy</h6> <p>One study reported on hypertensive disorders of pregnancy in a study that compared glibenclamide with a placebo (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Overall, for hypertensive disorders of pregnancy (any type) there was no difference between glibenclamide and placebo groups (risk ratio (RR) 1.24, 95% confidence interval (CI) 0.81 to 1.90; one study, n = 375 women; <a href="./references#CD011967-fig-0004" title="">Analysis 1.1</a>). Using GRADE the quality of the evidence was judged to be very low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and publication bias, as the evidence was only based on a single study. The risk of developing a hypertensive disorder of pregnancy in the placebo group was 16.7%, if the woman had been treated with glibenclamide the risk would range from 13.5% to 31.7% (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>For pregnancy‐induced hypertension (persistent systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg) there was no difference between glibenclamide and placebo groups (RR 1.24, 95% CI 0.71 to 2.19; one study, n = 375 women; Analysis 1.1 ). For severe pregnancy‐induced hypertension (proteinuria ≥ 2 g in 24 hours, or ≥ 2+ on dipstick, blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg, serum creatinine &gt; 1.0 mg/dL, platelets &lt; 100,000/mm<sup>3</sup>, aspartate aminotransferase &gt; 90 units/L, or symptoms such as persistent headache, scotomata or epigastric pain) there was no difference between glibenclamide and placebo groups (RR 1.23, 95% CI 0.59 to 2.56; one study, 375 women; <a href="./references#CD011967-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011967-sec-0136"> <h6 class="title">1.2 Caesarean section</h6> <p>One study reported on caesarean section in a study that compared glibenclamide with a placebo (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). There was no difference in the risk for birth by caesarean section between glibenclamide and placebo groups (RR 1.03, 95% CI 0.79 to 1.34; one study, n = 375 women; <a href="./references#CD011967-fig-0005" title="">Analysis 1.2</a>). Using GRADE the quality of the evidence was judged to be very low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and publication bias, as the evidence was only based on a single study. The risk of birth by caesarean section in the placebo group was 36%. For women treated with glibenclamide the risk would range from 28.5% to 48.3% (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011967-sec-0137"> <h6 class="title">Development of type 2 diabetes</h6> <p>None of the included trials comparing oral anti‐diabetic pharmacological therapies with placebo pre‐specified development of type 2 diabetes as a study outcome. </p> </section> </section> <section id="CD011967-sec-0138"> <h5 class="title">Neonatal primary outcomes</h5> <section id="CD011967-sec-0139"> <h6 class="title">1.3 LGA (90th percentile and above)</h6> <p>There was no difference in the risk of being born LGA age between infants whose mothers had been treated with glibenclamide and those who had received placebo (RR 0.89, 95% CI 0.51 to 1.58; one study, 375 infants; <a href="./references#CD011967-fig-0006" title="">Analysis 1.3</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Using GRADE the quality of the evidence was judged to be low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and publication bias as the evidence was only based on a single study. The risk of being born LGA if the mother had been treated with placebo was 11.8%, if the mother had been treated with glibenclamide the risk would have ranged from 6% to 18.7%. </p> </section> <section id="CD011967-sec-0140"> <h6 class="title">Other neonatal primary outcomes</h6> <p>None of the included trials comparing oral anti‐diabetic pharmacological therapies with placebo pre‐specified perinatal death and later infant mortality, death or serious morbidity composite or neurosensory disability in later childhood as study outcomes. </p> </section> </section> <section id="CD011967-sec-0141"> <h5 class="title">Maternal secondary outcomes</h5> <p><b>1.4 Use of additional pharmacotherapy</b> </p> <p>There was no evidence of a difference in the need for insulin between the anti‐diabetic pharmacological therapy and placebo groups reported in two studies (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>; <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>) (RR 0.68, 95% CI 0.42 to 1.11; two studies, n = 434 women; <a href="./references#CD011967-fig-0007" title="">Analysis 1.4</a>). The <a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> study used glibenclamide and the <a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> study used acarbose as the pharmacological intervention. <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> reported that 15/19 women in the standard care group were prescribed metformin and two women required insulin. It is not clear if any of the women in the metformin group required supplementary insulin. </p> <section id="CD011967-sec-0142"> <h6 class="title">1.5 Glycaemic control during/end of treatment</h6> <p>Glibenclamide was associated with a reduction in fasting capillary glucose concentrations taken at the last three antenatal visits compared with placebo (mean difference (MD) ‐3.00 mg/dL, 95% CI ‐5.13 to ‐0.87; one study, n = 375 women; <a href="./references#CD011967-fig-0008" title="">Analysis 1.5</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Caution is required in interpreting these data from a single trial with evidence of imprecision. </p> </section> <section id="CD011967-sec-0143"> <h6 class="title">1.6 Weight gain in pregnancy</h6> <p>There was no evidence of a difference between glibenclamide and placebo groups for weight gain during pregnancy (MD 0.00 Kg, 95% CI ‐0.96 to 0.96; one study, n = 375 women; <a href="./references#CD011967-fig-0009" title="">Analysis 1.6</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Caution is required in interpreting these data from a single trial with evidence of imprecision. </p> </section> <section id="CD011967-sec-0144"> <h6 class="title">1.7 Induction of labour</h6> <p>There was no evidence of a difference between glibenclamide and placebo groups for the risk of induction of labour reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (RR 1.18, 95% CI 0.79 to 1.76; one study, n = 375 women; <a href="./references#CD011967-fig-0010" title="">Analysis 1.7</a>). Using GRADE the quality of the evidence was judged to be very low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and therefore the evidence may not be generalisable; and publication bias, as the evidence was only based on a single study. The risk for induction of labour in the placebo group was 18.8%, if the woman was treated with glibenclamide the risk would range from 14.9% to 33.1% (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011967-sec-0145"> <h6 class="title">1.8 Perineal trauma/tearing</h6> <p>There was no evidence of a difference between glibenclamide and placebo groups for the risk of perineal trauma reported as third‐ to fourth‐degree tear reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (RR 0.98, 95% CI 0.06 to 15.62; one study, n = 375 women; <a href="./references#CD011967-fig-0011" title="">Analysis 1.8</a>). Using GRADE the quality of the evidence was judged to be very low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and wide CIs crossing the line of no effect and low event rates were suggestive of imprecision and publication bias, as the evidence was only based on a single study. If the risk of perineal trauma in the placebo group was 0.5%, then between 0% to 8% of the women treated with glibenclamide would be at risk of perineal trauma (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011967-sec-0146"> <h6 class="title">Other maternal secondary outcomes</h6> <p>No data were reported for any of the other pre‐specified maternal secondary outcomes for this review (maternal hypoglycaemia, adherence to the intervention, placental abruption, postpartum haemorrhage, breastfeeding at discharge, six weeks postpartum, six months or longer, maternal mortality, sense of well‐being and quality of life, behavioural changes associated with the intervention, views of the intervention, relevant biomarker changes associated with the intervention). </p> </section> </section> <section id="CD011967-sec-0147"> <h5 class="title">Long‐term maternal outcomes</h5> <p>No data were reported for long‐term maternal outcomes (post‐natal depression, BMI, postnatal weight retention or return to pre‐pregnancy weight, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, subsequent GDM, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome). </p> </section> <section id="CD011967-sec-0148"> <h5 class="title">Neonatal secondary outcomes</h5> <section id="CD011967-sec-0149"> <h6 class="title">1.9 Stillbirth</h6> <p>One study reported on stillbirth (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). There was no evidence of a difference in the risk of stillbirth between the glibenclamide and placebo groups (RR 0.49, 95% CI 0.05 to 5.38; one study, n = 375 infants; <a href="./references#CD011967-fig-0012" title="">Analysis 1.9</a>). Using GRADE the quality of the evidence was judged to be very low. This was due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and wide CIs crossing the line of no effect and low event rates were suggestive of imprecision and publication bias, as the evidence was only based on a single study. If the risk of stillbirth was 1.1% for the placebo group, between 0.1% to 5.8% of infants would have been stillborn if the woman was treated with glibenclamide. </p> </section> <section id="CD011967-sec-0150"> <h6 class="title">1.10 Neonatal death</h6> <p>There were no events of neonatal death reported in either the glibenclamide or the placebo group in one study including 375 infants (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). </p> </section> <section id="CD011967-sec-0151"> <h6 class="title">1.11 Small‐for‐gestational age</h6> <p>There was no evidence of a difference in the risk of being born small‐for‐gestational age between the glibenclamide and placebo groups reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (RR 1.11, 95% CI 0.58 to 2.10; one study, n = 375 infants; <a href="./references#CD011967-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD011967-sec-0152"> <h6 class="title">1.12 Macrosomia</h6> <p>There was no evidence of a difference in the risk of macrosomia (≥ 4 kg) between infants whose mothers had been treated with glibenclamide and those who had received placebo reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (RR 0.71, 95% CI 0.36 to 1.41; one study, n = 375 infants; <a href="./references#CD011967-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD011967-sec-0153"> <h6 class="title">1.13 Birthweight</h6> <p>There was no evidence of a difference in birthweight between infants whose mothers had been treated with glibenclamide and those who had received placebo reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (MD ‐33.00 g, 95% CI ‐134.53 to 68.53; one study, n = 375 infants). </p> </section> <section id="CD011967-sec-0154"> <h6 class="title">1.14 to 1.16 Birth trauma (shoulder dystocia, bone fracture, nerve palsy)</h6> <p>Birth trauma was reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) comparing glibenclamide with placebo. There was no evidence of a difference in the risk for shoulder dystocia (RR 0.33, 95% CI 0.01 to 8.00; one study, n = 375 infants; <a href="./references#CD011967-fig-0017" title="">Analysis 1.14</a>); bone fracture (RR 0.74, 95% CI 0.17 to 3.25; one study, n = 375 infants; <a href="./references#CD011967-fig-0018" title="">Analysis 1.15</a>) or nerve palsy (RR 0.33, 95% CI 0.01 to 8.00; one study, n = 375; <a href="./references#CD011967-fig-0018" title="">Analysis 1.15</a>) between the glibenclamide and placebo groups. Caution is required when interpreting these data due to low event rates and wide CIs crossing the line of no effect suggesting imprecision. </p> </section> <section id="CD011967-sec-0155"> <h6 class="title">1.17 Gestational age at birth</h6> <p>There was no evidence of a difference between glibenclamide and placebo groups for the gestational age at birth (MD 0.00 weeks, 95% CI ‐0.32 to 0.32; one study, n = 375 infants; <a href="./references#CD011967-fig-0020" title="">Analysis 1.17</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). </p> </section> <section id="CD011967-sec-0156"> <h6 class="title">1.18 Neonatal hypoglycaemia</h6> <p>There was no evidence of a difference in the risk for neonatal hypoglycaemia between the glibenclamide and the placebo groups (RR 1.97, 95% CI 0.36 to 10.62; one study, n = 375 infants; <a href="./references#CD011967-fig-0021" title="">Analysis 1.18</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Caution is required when interpreting these data due to low event rates and wide CIs crossing the line of no effect suggesting imprecision. Using GRADE the quality of the evidence was judged to be very low due to no published protocol being identified; more outcomes being reported than were listed in the trial registration documentation; evidence of indirectness, as 93% of population were Hispanic and evidence may not be generalisable; and wide CIs crossing the line of no effect and low event rates were suggestive of imprecision and publication bias, as the evidence was only based on a single study. If the risk of neonatal hypoglycaemia in the placebo group was 11%, between 4% to 11.4% of infants would experience hypoglycaemia if the woman was treated with glibenclamide. </p> </section> <section id="CD011967-sec-0157"> <h6 class="title">1.19 Neonatal jaundice (hyperbilirubinaemia)</h6> <p>There was no evidence of a difference in the risk for neonatal jaundice between the glibenclamide and the placebo groups reported in one study (RR 1.97, 95% CI 0.50 to 7.75; one study, n = 375 infants; <a href="./references#CD011967-fig-0022" title="">Analysis 1.19</a>) (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). </p> </section> <section id="CD011967-sec-0158"> <h6 class="title">Other neonatal secondary outcomes</h6> <p>No data were reported for any of the other neonatal secondary outcomes for this review (preterm birth (less than 37 weeks’ gestation; and less than 32 weeks' gestation), five‐minute Apgar less than seven, birthweight z score, head circumference and z score, length and z score, ponderal index, adiposity, respiratory distress syndrome, hypocalcaemia, polycythaemia, relevant biomarker changes associated with the intervention). </p> </section> </section> <section id="CD011967-sec-0159"> <h5 class="title">Later infant/childhood outcomes</h5> <p>No data were reported for childhood outcomes (weight and z scores, height and z scores, head circumference and z scores, adiposity, educational attainment, blood pressure, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic syndrome). </p> </section> <section id="CD011967-sec-0160"> <h5 class="title">Child as an adult outcomes</h5> <p>No data were reported for child as an adult outcomes (weight, height, adiposity, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome), employment, education and social status/achievement, dyslipidaemia or metabolic syndrome, type 1 diabetes, type 2 diabetes, impaired glucose tolerance). </p> </section> <section id="CD011967-sec-0161"> <h5 class="title">Health service outcomes</h5> <section id="CD011967-sec-0162"> <h6 class="title">1.20 Admission to NICU</h6> <p>There was no evidence of a difference in the risk of admission to neonatal intensive care between the glibenclamide and the placebo groups reported in one study (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>) (RR 1.16, 95% CI 0.53 to 2.53; one study, n = 375 infants; <a href="./references#CD011967-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD011967-sec-0163"> <h6 class="title">Other health service outcomes</h6> <p>No data were reported for the remaining health service outcomes (number of antenatal visits or admissions, number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse), length of antenatal stay, length of postnatal stay (maternal), length of postnatal stay (baby), cost of maternal care, cost of offspring care, costs associated with the intervention, costs to families associated with the management provided, cost of dietary monitoring (e.g. diet journals, dietician, nurse visits, etc), costs to families ‐ change of diet, extra antenatal visits, extra use of healthcare services (consultations, blood glucose monitoring, length and number of antenatal visits), women’s view of treatment advice, duration of stay in neonatal intensive care unit or special care baby unit). </p> </section> </section> </section> <section id="CD011967-sec-0164"> <h4 class="title">Metformin versus glibenclamide (comparison 2)</h4> <p>Six studies compared metformin with glibenclamide (<a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a>; <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). </p> <section id="CD011967-sec-0165"> <h5 class="title">Maternal primary outcomes</h5> <section id="CD011967-sec-0166"> <h6 class="title">2.1 Hypertensive disorders of pregnancy</h6> <p>Overall there was no evidence of a difference between metformin and glibenclamide‐treated groups for the risk of hypertensive disorders of pregnancy (any definition) (RR 0.70, 95% CI 0.38 to 1.30; three studies, n = 508 women; <a href="./references#CD011967-fig-0024" title="">Analysis 2.1</a>). Using GRADE the quality of the evidence was judged to be moderate, due to the trials being open‐label. If the risk of developing a hypertensive disorder of pregnancy was 8.8% in the glibenclamide group; for those treated with metformin the risk would range from 3.3% to 11.4%. </p> <p>One study reported data for pre‐eclampsia (not defined) (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). There was no evidence of a difference in the risk for pre‐eclampsia (not defined) between women who had been treated with metformin and those who had been treated with glibenclamide (RR 0.66, 95% CI 0.11 to 3.82; one study, n = 149 women). Two studies reported on pregnancy‐induced hypertension, <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> did not provide a definition and <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> reported on the presence of chronic arterial systemic hypertension (no further details). There was no difference in the risk for pregnancy‐induced hypertension between women who had been treated with metformin and those who had been treated with glibenclamide (RR 0.71, 95% CI 0.37 to 1.37; two studies, n = 359 women (<a href="./references#CD011967-fig-0024" title="">Analysis 2.1</a>). </p> </section> <section id="CD011967-sec-0167"> <h6 class="title">2.2 Caesarean section</h6> <p>Four studies reported data for caesarean section (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). There was no evidence of a difference in the risk for birth by caesarean section between women who had been treated with metformin and those who had been treated with glibenclamide (average RR 1.20, 95% CI 0.83 to 1.72; four studies, n = 554 women; I<sup>2</sup> = 61%, Tau<sup>2</sup> = 0.07) and the heterogeneity could not be explained through the diagnostic criteria used (<a href="./references#CD011967-fig-0025" title="">Analysis 2.2</a>). We excluded the study by <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> as this had unclear risk of bias for allocation concealment; heterogeneity increased to I<sup>2</sup> = 69%, Tau<sup>2</sup> = 0.11. The results of the <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> study, which included primarily Hispanic women with a mean BMI greater than 30 kg/m<sup>2</sup>, appeared to differ from the other studies and, when removed from the meta‐analysis, heterogeneity was reduced from I<sup>2</sup> = 61% to I<sup>2</sup> = 0% (RR 1.01, 95% CI 0.86 to 1.20; three studies, n = 405 women). The lack of difference between the metformin and glibenclamide groups for the chance of birth by caesarean section remained unaltered by the removal of <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>. Using GRADE the overall quality of the evidence was low due to lack of blinding and substantial heterogeneity. If the risk of birth by caesarean section when the woman had been treated with glibenclamide was 39.2%, the risk if the woman had been treated with metformin would have ranged from 32.5% to 67.4%. </p> </section> <section id="CD011967-sec-0168"> <h6 class="title">Development of type 2 diabetes</h6> <p>No data were reported for development of type 2 diabetes in any of the included studies for this comparison. </p> </section> </section> <section id="CD011967-sec-0169"> <h5 class="title">Neonatal primary outcomes</h5> <section id="CD011967-sec-0170"> <h6 class="title">2.3 Perinatal death</h6> <p>Two studies reported data for perinatal death, <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> reported no events in either the metformin or the glibenclamide groups; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> reported one stillbirth in each group (RR 0.92, 95% CI 0.06 to 14.55; two studies, n = 359 infants) (<a href="./references#CD011967-fig-0026" title="">Analysis 2.3</a>). Using GRADE the quality of the evidence was considered to be very low due to lack of blinding, imprecision and low event rates. If the risk of perinatal death when the mother had been treated with glibenclamide was 6%, the risk if the mother had been treated with metformin would have ranged from 0% to 8.3%. </p> </section> <section id="CD011967-sec-0171"> <h6 class="title">2.4 LGA</h6> <p>There was no evidence of a difference in the risk of being born LGA when the mother was treated with metformin compared with glibenclamide reported in two studies (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) (average RR 0.67, 95% CI 0.24 to 1.83; two studies, n = 246 infants; random‐effects model, I<sup>2</sup> = 54%, Tau<sup>2</sup> = 0.30) (<a href="./references#CD011967-fig-0027" title="">Analysis 2.4</a>). Both studies defined LGA as being greater than 90th percentile in growth curves. The subgroup interaction test for diagnostic criteria used was not significant suggesting that there was no differential effect based on diagnostic criteria. Using GRADE the quality of the evidence was considered to be low due to imprecision and heterogeneity. If the risk of being born LGA if the mother had been treated with glibenclamide was 19%, the risk if the mother had been treated with metformin would have ranged from 4.6% to 35.4%. </p> </section> <section id="CD011967-sec-0172"> <h6 class="title">2.5 Death or serious morbidity composite</h6> <p>One study (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>) reported data for a composite of neonatal outcomes that included hypoglycaemia, hyperbilirubinaemia, macrosomia, respiratory illness, birth injury, stillbirth or neonatal death. Metformin was associated with a reduction in the risk of the composite outcome compared with glibenclamide (RR 0.54, 95% CI 0.31 to 0.94; one study, n = 159 infants; <a href="./references#CD011967-fig-0028" title="">Analysis 2.5</a>). The evidence should be interpreted with caution as it is based on a single small study. Using GRADE the quality of the evidence was judged to be low due to lack of blinding and publication bias. If the risk of mortality or serious neonatal mortality was 35% if the mother had been treated with glibenclamide, the risk if the mother had been treated with metformin would have ranged from 10.9% to 32.9%. </p> </section> <section id="CD011967-sec-0173"> <h6 class="title">Neurosensory disability in later childhood</h6> <p>No data were reported for neurosensory disability in later childhood for this comparison.</p> </section> </section> <section id="CD011967-sec-0174"> <h5 class="title">Maternal secondary outcomes</h5> <section id="CD011967-sec-0175"> <h6 class="title">2.6 Use of additional pharmacotherapy</h6> <p>Five studies reported on the need for additional pharmacological therapy (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). There was no evidence of a difference in the risk of requiring supplemental insulin between women who had been treated with metformin and those treated with glibenclamide (RR 0.66, 95% CI 0.28 to 1.57; five studies, n = 660 women; random‐effects model, I<sup>2</sup> = 72%, Tau<sup>2</sup> = 0.57; <a href="./references#CD011967-fig-0029" title="">Analysis 2.6</a>). The heterogeneity could not be explained through the diagnostic criteria used (data not shown). In sensitivity analysis we removed two studies which had unclear risk of bias for allocation concealment (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>); heterogeneity was not affected by their removal (I<sup>2</sup> = 77%, Tau<sup>2</sup> = 0.50) (data not shown). The <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> study again appeared to have data that differed from the other studies included in the meta‐analysis and exclusion of this study reduced heterogeneity to I<sup>2</sup> = 8% but also suggested that the use of metformin was associated with a reduced requirement for additional pharmacotherapy (RR 0.56, 95% CI 0.33 to 0.95; four studies, n = 511 women). The authors of the <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> study suggested that their findings may differ from those of other studies as their study population comprised Hispanic women and they believe there may be an ethnically differential response to metformin in these women. </p> </section> <section id="CD011967-sec-0176"> <h6 class="title">2.7 Maternal hypoglycaemia</h6> <p>Three studies reported on maternal hypoglycaemia. <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> and <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> did not provide any definitions of maternal hypoglycaemia and <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> used a cut off of 3.3 mmol/L (60 mg/dL). There was no difference in the risk of maternal hypoglycaemia between women who had been treated with metformin and those treated with glibenclamide (RR 0.89, 95% CI 0.36 to 2.19; three studies, n = 354 women; <a href="./references#CD011967-fig-0030" title="">Analysis 2.7</a>). The <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> study, currently published as a conference abstract, reported data for women who dropped out of the study with hypoglycaemia. Thirty‐nine percent of women in the glibenclamide group (17/45) and 3% of women in the metformin group (1/36) "dropped out" of the study due to maternal hypoglycaemia. It is unclear whether they withdrew from the study due to treatment side effects or were lost to follow‐up. </p> </section> <section id="CD011967-sec-0177"> <h6 class="title">2.8 Glycaemic control during/at end of treatment</h6> <p>Three studies reported fasting and postprandial blood glucose concentrations (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>) and one study (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) reported HbA1c concentration . </p> <p>Metformin was associated with an increase in fasting blood glucose concentration compared with glibenclamide (standardised mean difference (SMD) 0.19, 95% CI 0.02 to 0.37; three studies, n = 508 women; <a href="./references#CD011967-fig-0031" title="">Analysis 2.8</a>). There was no difference between metformin and glibenclamide for two‐hour (after dinner, where reported) post‐prandial blood glucose concentration (SMD 0.16, 95% CI ‐0.01 to 0.34; three studies, n = 508 women; <a href="./references#CD011967-fig-0031" title="">Analysis 2.8</a>). The data for <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> are for one‐hour postprandial (mealtime not specified). </p> <p>One study (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) found no evidence of a difference in HbA1c concentration in the third trimester of the pregnancy between treatment with metformin and treatment with glibenclamide (SMD ‐0.12 %, 95% CI ‐0.39 to 0.16; one study, n = 200 women). The <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> study, currently published as a conference abstract, reported data for women who "dropped out" of the study as they were unable to attain glycaemic control. Fourteen per cent of the women in the glibenclamide group (6/45) and 3% in the metformin group (1/36) dropped out because they were unable to maintain glycaemic control. </p> </section> <section id="CD011967-sec-0178"> <h6 class="title">2.9 Weight gain in pregnancy</h6> <p>Metformin was associated with a reduced weight during pregnancy compared with glibenclamide, reported by one study (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) (MD ‐2.06 Kg, 95% CI ‐3.98 to ‐0.14; one study, n = 200 women; <a href="./references#CD011967-fig-0032" title="">Analysis 2.9</a>). </p> </section> <section id="CD011967-sec-0179"> <h6 class="title">2.10 Induction of labour</h6> <p>One study (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>) found no evidence of a difference in the risk for induction of labour between women who had been treated with metformin and those treated with glibenclamide (RR 0.81, 95% CI 0.61 to 1.07; one study; n = 159 women; <a href="./references#CD011967-fig-0033" title="">Analysis 2.10</a>). Using GRADE the quality of the evidence was judged to be low due to lack of blinding and publication bias. If the risk for induction of labour if treated with glibenclamide was 61.3%, the risk if treated with metformin would have ranged from 37.4% to 65.5%. </p> </section> <section id="CD011967-sec-0180"> <h6 class="title">2.11 Perineal trauma/tearing</h6> <p>There was no evidence of a difference in the risk for third or fourth degree perineal tearing between women who had been treated with metformin and those treated with glibenclamide reported in two studies (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>) (RR 1.67, 95% CI 0.22 to 12.52; two studies, n = 308 women; <a href="./references#CD011967-fig-0034" title="">Analysis 2.11</a>). Using GRADE the quality of the evidence was judged to be low due to lack of blinding, imprecision and low event rates. If the risk of perineal trauma for women treated with glibenclamide was 0.6%, for those treated with metformin the risk would have ranged from 0.1% to 8%. </p> </section> <section id="CD011967-sec-0181"> <h6 class="title">Other maternal secondary outcomes</h6> <p>No data were reported for any of the remaining maternal secondary outcomes for this review (Adherence to the intervention, placental abruption, postpartum haemorrhage, postpartum infection, breastfeeding at discharge, six weeks postpartum, six months or longer, maternal mortality, sense of well‐being and quality of life, behavioural changes associated with the intervention, views of the intervention, relevant biomarker changes associated with the intervention). </p> </section> </section> <section id="CD011967-sec-0182"> <h5 class="title">Long‐term maternal outcomes</h5> <p>No data were reported for long‐term maternal outcomes (postnatal depression, BMI, postnatal weight retention or return to pre‐pregnancy weight, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, subsequent GDM, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome). </p> </section> <section id="CD011967-sec-0183"> <h5 class="title">Neonatal secondary outcomes</h5> <section id="CD011967-sec-0184"> <h6 class="title">2.12 Stillbirth</h6> <p>One study (<a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) found no evidence of a difference in the risk for fetal death for infants whose mothers had been treated with metformin or those treated with glibenclamide (RR 0.92, 95% CI 0.06 to 14.55; one study, n = 200 infants; <a href="./references#CD011967-fig-0035" title="">Analysis 2.12</a>). </p> </section> <section id="CD011967-sec-0185"> <h6 class="title">2.13 Macrosomia</h6> <p>Macrosomia was defined as birthweight of 3.7 kg or more by <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> and as 4.0 kg or more by <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>. There was no evidence of a difference in the risk for macrosomia for infants whose mothers had been treated with metformin or those treated with glibenclamide (RR 0.72, 95% CI 0.23 to 2.21; two studies, n = 308 infants; <a href="./references#CD011967-fig-0036" title="">Analysis 2.13</a>). </p> </section> <section id="CD011967-sec-0186"> <h6 class="title">2.14 to 2.15 Birth trauma; shoulder dystocia</h6> <p>One study reported no events of birth injury (no further details) in either the metformin‐ or the glibenclamide‐treated groups (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>). Two studies (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>) reported no evidence of a difference in the risk for shoulder dystocia for infants whose mothers had been treated with metformin or those treated with glibenclamide (RR 0.99, 95% CI 0.14 to 6.89; two studies, n = 195 infants) (<a href="./references#CD011967-fig-0038" title="">Analysis 2.15</a>). </p> </section> <section id="CD011967-sec-0187"> <h6 class="title">2.16 Gestational age at birth</h6> <p>There was no evidence of a difference in gestational age at birth for infants whose mothers had been treated with metformin or those treated with glibenclamide reported in three studies (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) (MD 0.03 weeks, 95% CI ‐0.22 to 0.28; three studies, n = 508 infants; <a href="./references#CD011967-fig-0039" title="">Analysis 2.16</a>). This is probably a reflection of local policies for timing of birth for women with GDM. </p> </section> <section id="CD011967-sec-0188"> <h6 class="title">2.17 Preterm birth (less than 37 weeks’ gestation);</h6> <p>There was no evidence of a difference in the risk for preterm birth (less than 37 weeks' gestation) for infants whose mothers had been treated with metformin or those treated with glibenclamide reported in three studies (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>) (RR 1.59, 95% CI 0.59 to 4.29; three studies, n = 508 infants; <a href="./references#CD011967-fig-0040" title="">Analysis 2.17</a>). </p> </section> <section id="CD011967-sec-0189"> <h6 class="title">2.18 Five‐minute Apgar less than seven</h6> <p>There were no events of a five‐minute Apgar score less than seven in either the metformin‐ or glibenclamide‐treated groups in the single study reporting this outcome (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>). <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> reported no difference in Apgar scores less than seven with 5/104 events for the metformin group and 5/96 events for the glibenclamide group. However, they do not specify if this is at the one minute or five‐minute assessment. </p> </section> <section id="CD011967-sec-0190"> <h6 class="title">2.19 Birthweight</h6> <p>Three studies reported on birthweight. <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> reported data adjusted for gestational age, maternal height and gender (metformin 3064 g ± 202 versus glibenclamide 3037 g ± 204). We did not include data from this study in the meta‐analysis because heterogeneity was I<sup>2</sup> = 86% when we included the study and I<sup>2</sup> = 0% when we removed it. We have contacted the study authors in an attempt to obtain the unadjusted data for birthweight. If these data are available we will add them to the meta‐analysis in the next update of this review. </p> <p>For the remaining two studies (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>), metformin was associated with a reduction in birthweight compared to glibenclamide (MD ‐209.13 g, 95% CI ‐314.53 to ‐103.73; two studies, I<sup>2</sup> = 0% n = 249 infants; <a href="./references#CD011967-fig-0042" title="">Analysis 2.19</a>). </p> </section> <section id="CD011967-sec-0191"> <h6 class="title">2.20 Ponderal index</h6> <p>Metformin was associated with a reduced ponderal index compared with glibenclamide reported by <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> (MD ‐0.09 units, 95% CI ‐0.17 to ‐0.01; one study, n = 200 infants; <a href="./references#CD011967-fig-0043" title="">Analysis 2.20</a>). </p> </section> <section id="CD011967-sec-0192"> <h6 class="title">2.21 Neonatal hypoglycaemia</h6> <p>There was no evidence of a difference in the risk for neonatal hypoglycaemia (defined as less than 2.2 mmol/L; 40 mg/dL) in infants whose mothers had been treated with metformin or those treated with glibenclamide (RR 0.86, 95% CI 0.42 to 1.77; four studies, n = 554 infants; <a href="./references#CD011967-fig-0044" title="">Analysis 2.21</a>). Using GRADE the quality of the evidence was judged to be low due to lack of blinding and low event rates suggesting imprecision. If the risk of neonatal hypoglycaemia in the group treated with glibenclamide was 4.8%, for those treated with metformin the risk ranged from 1.9% to 8.3%. </p> </section> <section id="CD011967-sec-0193"> <h6 class="title">2.22 Respiratory distress syndrome</h6> <p>There was no evidence of a difference in the risk for neonatal hypoglycaemia in infants whose mothers had been treated with metformin or those treated with glibenclamide reported by <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> (RR 0.51, 95% CI 0.10 to 2.69; one study, n = 159 infants; <a href="./references#CD011967-fig-0045" title="">Analysis 2.22</a>). </p> </section> <section id="CD011967-sec-0194"> <h6 class="title">2.23 Neonatal jaundice (hyperbilirubinaemia)</h6> <p>There was no evidence of a difference in the risk for hyperbilirubinaemia in infants whose mothers had been treated with metformin or those treated with glibenclamide reported by <a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> and <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> (RR 0.68, 95% CI 0.37 to 1.25; two studies, n = 205 infants; <a href="./references#CD011967-fig-0046" title="">Analysis 2.23</a>). </p> </section> <section id="CD011967-sec-0195"> <h6 class="title">Relevant biomarkers associated with the intervention</h6> <p>Cord C‐peptide greater than 1.7 micrograms per litre was reported in eight babies whose mothers had been treated with metformin and in five babies whose mothers had been treated with glibenclamide in one study (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>). </p> </section> <section id="CD011967-sec-0196"> <h6 class="title">Other outcomes not prespecified</h6> <p>The <a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> study, currently published as a conference abstract, reported data for women who dropped out of the study due to gastric intolerance. Two per cent of women (1/45) in the glibenclamide group and 17% in the metformin group (6/36) withdrew from the study due to gastric intolerance. </p> </section> <section id="CD011967-sec-0197"> <h6 class="title">Other secondary neonatal outcomes</h6> <p>No data were reported for the other neonatal secondary outcomes for this comparison (neonatal death, small‐for‐gestational age; bone fracture; nerve palsy; congenital malformation; head circumference and z scores; length and z scores; birthweight z scores, head circumference z scores, skinfold thickness measurements (mm); fat mass; hypocalcaemia; hypercalcaemia; polycythaemia). </p> </section> </section> <section id="CD011967-sec-0198"> <h5 class="title">Later infant/childhood outcomes</h5> <p>No data were reported for childhood outcomes (weight and z scores, height and z scores, head circumference and z scores, adiposity, educational attainment, blood pressure, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic syndrome). </p> </section> <section id="CD011967-sec-0199"> <h5 class="title">Child as an adult outcomes</h5> <p>No data were reported for child as an adulthood outcomes (weight, height, adiposity, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome), employment, education and social status/achievement, dyslipidaemia or metabolic syndrome, type 1 diabetes, type 2 diabetes, impaired glucose tolerance). </p> </section> <section id="CD011967-sec-0200"> <h5 class="title">Health service outcomes</h5> <section id="CD011967-sec-0201"> <h6 class="title">2.24 Admission to neonatal intensive care</h6> <p>There was no evidence of a difference for admission to the neonatal intensive care unit between the metformin‐ and glibenclamide‐treated groups reported by <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> and <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> (RR 1.52, 95% CI 0.65 to 3.56; two studies, n = 349 infants; <a href="./references#CD011967-fig-0047" title="">Analysis 2.24</a>). </p> </section> <section id="CD011967-sec-0202"> <h6 class="title">Other health service outcomes</h6> <p>No data were reported for other health service outcomes (number of antenatal visits or admissions, number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse), length of antenatal stay, length of postnatal stay (maternal), length of postnatal stay (baby), cost of maternal care, cost of offspring care, costs associated with the intervention, costs to families associated with the management provided, cost of dietary monitoring (e.g. diet journals, dietician, nurse visits, etc), costs to families ‐ change of diet, extra antenatal visits, extra use of healthcare services (consultations, blood glucose monitoring, length and number of antenatal visits), women’s view of treatment advice, duration of stay in neonatal intensive care unit or special care baby unit). </p> </section> </section> </section> <section id="CD011967-sec-0203"> <h4 class="title">Acarbose versus other oral anti‐diabetic agent (comparison 3)</h4> <p>We identified a single small study (n = 43) that compared glibenclamide with acarbose (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>). </p> <section id="CD011967-sec-0204"> <h5 class="title">Maternal primary outcomes</h5> <section id="CD011967-sec-0205"> <h6 class="title">3.1 Caesarean section</h6> <p>There was no evidence of a difference in the risk of caesarean section between women who had been treated with glibenclamide and those treated with acarbose (RR 0.95, 95% CI 0.53 to 1.70; one study, n = 43 women; low‐quality evidence; <a href="./references#CD011967-fig-0048" title="">Analysis 3.1</a>). The evidence was downgraded for risk of bias (method of randomisation was unclear) and imprecision (single small study). </p> </section> <section id="CD011967-sec-0206"> <h6 class="title">Other maternal primary outcomes</h6> <p>No data were reported on hypertensive disorders of pregnancy or on the development of type 2 diabetes for this comparison. </p> </section> </section> <section id="CD011967-sec-0207"> <h5 class="title">Neonatal primary outcomes</h5> <p><b>3.2 Perinatal death and later infant mortality</b> </p> <p>There were no cases of perinatal death for either glibenclamide<b>‐</b> or acarbose‐treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. Absolute effects could not be reported due to no events being reported for the outcome. The quality of the evidence was low due to selective reporting and evidence being based on a single study. </p> <section id="CD011967-sec-0208"> <h6 class="title">3.3 LGA</h6> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> found no evidence of a difference in the risk for being born LGA (greater than 90th percentile) between infants whose mothers had been treated with glibenclamide and those treated with acarbose (RR 2.38, 95% CI 0.54 to 10.46; one study, n = 43 women; <a href="./references#CD011967-fig-0050" title="">Analysis 3.3</a>). if the risk for being LGA was 10.5% in those infants whose mothers were treated with acarbose, between 5.7% to 100% of those whose mothers had been treated with glibenclamide would be born LGA. The quality of the evidence was judged to be low due to selective reporting and evidence being based on a single study. </p> </section> <section id="CD011967-sec-0209"> <h6 class="title">Other neonatal primary outcomes</h6> <p>No data were reported for death, serious morbidity composite or neurosensory disability in later childhood for this comparison. </p> </section> </section> <section id="CD011967-sec-0210"> <h5 class="title">Maternal secondary outcomes</h5> <section id="CD011967-sec-0211"> <h6 class="title">3.4 Use of additional pharmacotherapy</h6> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> reported no difference in the need for additional insulin between women who had been treated with glibenclamide and those treated with acarbose (RR 0.49, 95% CI 0.19 to 1.27; one study, n = 43 women; <a href="./references#CD011967-fig-0051" title="">Analysis 3.4</a>). </p> </section> <section id="CD011967-sec-0212"> <h6 class="title">3.5 Maternal hypoglycaemia</h6> <p>There were no events of maternal hypoglycaemia (requiring hospitalisation) for either glibenclamide‐ or acarbose‐treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. </p> </section> <section id="CD011967-sec-0213"> <h6 class="title">3.6 Weight gain in pregnancy</h6> <p>There was no evidence of a difference in weight gain in pregnancy between women who had been treated with glibenclamide and those treated with acarbose reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> (MD ‐0.60 Kg, 95% CI ‐3.13 to 1.93; one study, n = 43 women; <a href="./references#CD011967-fig-0053" title="">Analysis 3.6</a>). </p> </section> <section id="CD011967-sec-0214"> <h6 class="title">Other maternal secondary outcomes</h6> <p>No data were reported for the other maternal secondary outcomes of this review (glycaemic control during/end of treatment, adherence to the intervention, induction of labour, placental abruption, postpartum haemorrhage, postpartum infection, perineal trauma/tearing, breastfeeding at discharge, six weeks postpartum, six months or longer, maternal mortality, sense of well‐being and quality of life, behavioural changes associated with the intervention, views of the intervention, relevant biomarker changes associated with the intervention). </p> </section> </section> <section id="CD011967-sec-0215"> <h5 class="title">Long‐term maternal outcomes</h5> <p>No data were reported for long‐term maternal outcomes (postnatal depression, BMI, postnatal weight retention or return to pre‐pregnancy weight, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, subsequent GDM, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome). </p> </section> <section id="CD011967-sec-0216"> <h5 class="title">Neonatal secondary outcomes</h5> <section id="CD011967-sec-0217"> <h6 class="title">3.7 Macrosomia</h6> <p>There was no evidence of a difference in the risk of macrosomia (greater than 4 kg) for infants whose mothers had been treated with glibenclamide and those treated with acarbose (RR 7.20, 95% CI 0.41 to 125.97; one study, n = 43 women; <a href="./references#CD011967-fig-0054" title="">Analysis 3.7</a>). </p> </section> <section id="CD011967-sec-0218"> <h6 class="title">3.8 Small‐for‐gestational age</h6> <p>There were no events of being born small‐for‐gestational age (not defined) for either glibenclamide or acarbose treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. </p> </section> <section id="CD011967-sec-0219"> <h6 class="title">3.9 Birth trauma</h6> <p>There were no events of birth trauma (not specified) for either glibenclamide‐ or acarbose‐treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. </p> </section> <section id="CD011967-sec-0220"> <h6 class="title">3.10 Gestational age at birth</h6> <p>There was no evidence of a difference in gestational age at birth between infants whose mothers had been treated with glibenclamide and those treated with acarbose (MD ‐0.10 weeks, 95% CI ‐0.82 to 0.62; one study, n = 43 women; <a href="./references#CD011967-fig-0057" title="">Analysis 3.10</a>). </p> </section> <section id="CD011967-sec-0221"> <h6 class="title">3.11 Preterm birth</h6> <p>There were no events of preterm birth for either glibenclamide‐ or acarbose‐treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. </p> </section> <section id="CD011967-sec-0222"> <h6 class="title">3.12 Birthweight</h6> <p>There was no evidence of a difference in birthweight between infants whose mothers had been treated with glibenclamide and those treated with acarbose (MD 153.00 g, 95% CI ‐123.52 to 429.52; one study, n = 43 women; <a href="./references#CD011967-fig-0059" title="">Analysis 3.12</a> ). </p> </section> <section id="CD011967-sec-0223"> <h6 class="title">3.13 Neonatal hypoglycaemia</h6> <p>There was no evidence of a difference in the risk of neonatal hypoglycaemia (2.2 mmol/L; less than 40 mg/dL) for infants whose mothers had been treated with glibenclamide and those treated with acarbose (RR 6.33, 95% CI 0.87 to 46.32; one study, n = 43 women; low‐quality evidence; <a href="./references#CD011967-fig-0060" title="">Analysis 3.13</a>). If neonatal hypoglycaemia occurred in 5.3% of infants whose mothers had been treated with acarbose, the risk for those whose mothers had been treated with glibenclamide would range from 4.6% to 100%. The quality of the evidence was judged to be very low due to selective reporting, evidence being based on a single study and imprecision. </p> </section> <section id="CD011967-sec-0224"> <h6 class="title">3.14 Respiratory distress syndrome</h6> <p>There were no events of respiratory distress syndrome for either glibenclamide or acarbose treated women reported by <a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>. </p> </section> <section id="CD011967-sec-0225"> <h6 class="title">Other neonatal secondary outcomes</h6> <p>No other neonatal secondary outcomes were reported for this comparison (stillbirth, neonatal death, five‐minute Apgar less than seven, birthweight z score, head circumference and z score, length and z score, ponderal index, adiposity, neonatal jaundice (hyperbilirubinaemia), hypocalcaemia, polycythaemia, relevant biomarker changes associated with the intervention). </p> </section> </section> <section id="CD011967-sec-0226"> <h5 class="title">Later infant/childhood outcomes</h5> <p>No data were reported for childhood outcomes (weight and z scores, height and z scores, head circumference and z scores, adiposity, educational attainment, blood pressure, type 1 diabetes, type 2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic syndrome). </p> </section> <section id="CD011967-sec-0227"> <h5 class="title">Child as an adult outcomes</h5> <p>No data were reported for child as an adult outcomes (weight, height, adiposity, cardiovascular health (as defined by trialists including blood pressure, hypertension, cardiovascular disease, metabolic syndrome), employment, education and social status/achievement, dyslipidaemia or metabolic syndrome, type 1 diabetes, type 2 diabetes, impaired glucose tolerance). </p> </section> <section id="CD011967-sec-0228"> <h5 class="title">Health service outcomes</h5> <section id="CD011967-sec-0229"> <h6 class="title">Admission to neonatal intensive care</h6> <p>One infant in the glibenclamide group was admitted to neonatal intensive care. The difference was not significant when compared with acarbose (RR 2.49, 95% CI 0.10 to 64.62; one study, n = 43). </p> </section> <section id="CD011967-sec-0230"> <h6 class="title">Other health service outcomes</h6> <p>No data were reported for other health service outcomes (number of antenatal visits or admissions, number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse), admission to neonatal intensive care unit/nursery, length of antenatal stay, length of postnatal stay (maternal), length of postnatal stay (baby), cost of maternal care, cost of offspring care, costs associated with the intervention, costs to families associated with the management provided, cost of dietary monitoring (e.g. diet journals, dietician, nurse visits), costs to families ‐ change of diet, extra antenatal visits, extra use of healthcare services (consultations, blood glucose monitoring, length and number of antenatal visits), women’s view of treatment advice, duration of stay in neonatal intensive care unit or special care baby unit). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011967-sec-0231" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011967-sec-0231">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011967-sec-0294">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011967-sec-0231"></div> <section id="CD011967-sec-0232"> <h3 class="title" id="CD011967-sec-0232">Summary of main results</h3> <p>There was no evidence of a difference between women treated with oral anti‐diabetic pharmacological therapies compared with placebo for hypertensive disorders of pregnancy, induction of labour, perineal trauma or risk of birth by caesarean section (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>). Oral anti‐diabetic pharmacological therapy did appear to lower fasting capillary blood glucose concentrations compared with placebo in one study of 375 Hispanic women (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). No data were reported for development of type 2 diabetes or return to pre‐pregnancy weight or postnatal depression. There was no evidence of a difference in the risk for being born LGA between infants whose mothers received glibenclamide or placebo (<a href="./full#CD011967-tbl-0002">summary of findings Table 2</a>). There was no evidence of a difference in the risk of macrosomia or in birthweight between infants whose mothers had been treated with glibenclamide and those treated with placebo. No data were reported for perinatal mortality, death or serious morbidity composite, neonatal hypoglycaemia, diabetes or adiposity. Evidence was limited to two studies both of which used a different oral anti‐diabetic pharmacological therapy. Outcomes of interest for this review were poorly reported. </p> <p>We found few differences between groups for the comparison of metformin versus glibenclamide. Metformin was associated with an increase in fasting blood glucose levels compared with glibenclamide, but no difference in postprandial glucose levels (<a href="./full#CD011967-tbl-0003">summary of findings Table 3</a>). There was no evidence of a difference between groups for hypertensive disorders of pregnancy, birth by caesarean section, perineal trauma or induction of labour. No data were reported for postnatal depression or development of type 2 diabetes. Metformin was associated with a reduced risk of death or serious morbidity composite (hypoglycaemia, hyperbilirubinaemia, macrosomia, respiratory illness, birth injury, stillbirth or neonatal death) compared with glibenclamide. There was no evidence of a difference between groups for being born LGA, perinatal mortality or neonatal hypoglycaemia. No data were reported for adiposity of diabetes (<a href="./full#CD011967-tbl-0004">summary of findings Table 4</a>). The evidence for each outcome was based on a limited number of studies with low sample size. </p> <p>The limited evidence for glibenclamide versus acarbose did not identify any differences between groups for the limited maternal and infant outcomes that were reported. There was no evidence of a difference between groups for birth by caesarean section. No data were reported for hypertensive disorders of pregnancy, induction of labour, development of type 2 diabetes, perineal trauma, return to pre‐pregnancy weight or postnatal depression (<a href="./full#CD011967-tbl-0005">summary of findings Table 5</a>). There were no events reported in either group for perinatal mortality. There was no evidence of a difference between groups for being born LGA or neonatal hypoglycaemia. No data were reported for death or serious morbidity composite, adiposity or diabetes (<a href="./full#CD011967-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD011967-sec-0233"> <h3 class="title" id="CD011967-sec-0233">Overall completeness and applicability of evidence</h3> <p>All of the studies reported on women with GDM, although the proportion of women with GDM in the <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> study could not be clearly ascertained and therefore we could not include the data in a meta‐analysis. The number of studies identified was limited for some of the comparisons. In one study we questioned the generalisability of the data due to the demographics of the women recruited being 93% Hispanic (<a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a>). Oral anti‐diabetic agent versus placebo or usual care was reported as a comparison by three studies<i>(</i><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a>; <a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a>; <a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a>); metformin versus glibenclamide was reported by four studies (<a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a>; <a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>); one study compared glibenclamide with acarbose (<a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a>) and one study compared glibenclamide with the addition of metformin if glycaemic targets were not met against metformin with the addition of glibenclamide if glycaemic targets were not met (<a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a>). </p> <p>No data were reported on long‐term maternal or neonatal/child outcomes and no data were reported on direct or indirect costs of the interventions. Health service outcomes were very poorly reported. </p> <p>Clinicians and women may also be interested in the comparison of oral anti‐diabetic pharmacological therapies compared with insulin and we refer the reader to another Cochrane Review that includes this comparison (<a href="./references#CD011967-bbs2-0031" title="BrownJ , GrzeskowiakL , WilliamsonK , DownieMR , CrowtherCA . Insulin for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD012037] ">Brown 2016</a>). </p> <p>None of the studies reported long‐term GRADE outcomes for development of type 2 diabetes and postnatal depression for the mother, and none reported adiposity and diabetes for the infants. </p> </section> <section id="CD011967-sec-0234"> <h3 class="title" id="CD011967-sec-0234">Quality of the evidence</h3> <p>Eleven included studies (1487 women and their babies) were identified. Two studies are awaiting classification. Overall we judged the evidence to be of unclear risk of bias due to lack of methodological details provided in the individual studies. </p> <p>Two studies reported data for the comparison of oral anti‐diabetic pharmacological therapies versus placebo, the main methodological limitations were a lack of adequate reporting to make a judgement regarding risk of bias, lack of generalisability and evidence being based on a single study for many of the reported outcomes. The overall quality of the evidence was judged to be very low using GRADE methodology (<a href="./full#CD011967-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011967-tbl-0002">summary of findings Table 2</a>. </p> <p>Six studies reported data for the comparison of metformin and glibenclamide, the most commonly used oral anti‐diabetic pharmacological therapies. The evidence was generally of moderate to low quality and was downgraded due to lack of blinding, imprecision and evidence being based on a single trial (<a href="./full#CD011967-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011967-tbl-0004">summary of findings Table 4</a>). </p> <p>One study reported on the comparison of glibenclamide versus acarbose, the evidence was considered to be of low quality in the one outcome of interest for this review that was reported and used for assessment of quality using GRADE. The evidence was downgraded for unclear randomisation and only being based on a single study (<a href="./full#CD011967-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011967-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD011967-sec-0235"> <h3 class="title" id="CD011967-sec-0235">Potential biases in the review process</h3> <p>We conducted a comprehensive search of the literature including both full papers and conference abstracts with no language restrictions. Two researchers independently undertook identification of studies for inclusion in this review, data extraction and data entry. The main limitation of this systematic review is the lack of studies overall and a lack of studies for each comparison. We could not include any data in meta‐analyses for chlorpropamide or tolbutamide. These drugs are known to cross the placenta and, due to concerns about risks of congenital abnormalities, are not recommended during pregnancy in high‐ and middle‐income countries. We could not estimate the extent of their use in low‐income countries. There was a lack of data reported for the outcomes of interest for this review. Long‐term outcomes were not reported. </p> </section> <section id="CD011967-sec-0236"> <h3 class="title" id="CD011967-sec-0236">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review by <a href="./references#CD011967-bbs2-0024" title="BalsellsM , Garcia‐PattersonA , SolàI , RoquéM , GichI , CorcoyR . Glibenclamide, metformin and insulin for the treatment of gestational diabetes: a systematic review and meta‐analysis. BMJ2015;350:h102. ">Balsells 2015</a> included a head‐to‐head comparison of metformin with glibenclamide and included two studies (<a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>), both of which are included in this review. Our results concur with the majority of their findings although <a href="./references#CD011967-bbs2-0024" title="BalsellsM , Garcia‐PattersonA , SolàI , RoquéM , GichI , CorcoyR . Glibenclamide, metformin and insulin for the treatment of gestational diabetes: a systematic review and meta‐analysis. BMJ2015;350:h102. ">Balsells 2015</a> reported that metformin was associated with a reduction in the risk of being born LGA or macrosomic whereas our analyses suggest no difference between metformin and glibenclamide for these outcomes. Another systematic review (<a href="./references#CD011967-bbs2-0022" title="AminM , SuksomboonN , PoolsupN , MalikO . Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta‐analysis. Clinical Drug Investigation2015;35(6):343‐51. ">Amin 2015</a>) compared glibenclamide with metformin in three included studies (<a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a>; <a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a>; <a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a>). Their data and that of our review are in agreement, with the exception of LGA and macrosomia, which the <a href="./references#CD011967-bbs2-0022" title="AminM , SuksomboonN , PoolsupN , MalikO . Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta‐analysis. Clinical Drug Investigation2015;35(6):343‐51. ">Amin 2015</a> systematic review combined in a composite outcome that reflected an increased risk in infants whose mothers had been treated with glibenclamide (RR 1.94, 95%CI 1.03 to 3.66; three studies, 508 infants) and for which our systematic review reports data separately, finding no evidence of a difference either for macrosomia (RR 0.72, 95%CI 0.23 to 2.21; two studies, 308 infants) or LGA (RR 0.67, 95%CI 0.24 to 1.83; two studies, 246 infants). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011967-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 1 Hypertensive disorders of pregnancy." data-id="CD011967-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 1 Hypertensive disorders of pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 2 Caesarean section." data-id="CD011967-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 2 Caesarean section.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 3 Large‐for‐gestational age." data-id="CD011967-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 3 Large‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 4 Use of additional pharmacotherapy." data-id="CD011967-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 4 Use of additional pharmacotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 5 Glycaemic control (end of treatment) (mg/dL)." data-id="CD011967-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 5 Glycaemic control (end of treatment) (mg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 6 Weight gain in pregnancy (Kg)." data-id="CD011967-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 6 Weight gain in pregnancy (Kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 7 Induction of labour." data-id="CD011967-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 7 Induction of labour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 8 Perineal trauma." data-id="CD011967-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 8 Perineal trauma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 9 Stillbirth." data-id="CD011967-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 9 Stillbirth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 10 Neonatal death." data-id="CD011967-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 10 Neonatal death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 11 Small‐for‐gestational age." data-id="CD011967-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 11 Small‐for‐gestational age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 12 Macrosomia." data-id="CD011967-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 12 Macrosomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 13 Birthweight (g)." data-id="CD011967-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 13 Birthweight (g).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 14 Shoulder dystocia." data-id="CD011967-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 14 Shoulder dystocia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 15 Bone fracture." data-id="CD011967-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 15 Bone fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 16 Nerve palsy." data-id="CD011967-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 16 Nerve palsy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 17 Gestational age at birth (weeks)." data-id="CD011967-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 17 Gestational age at birth (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 18 Neonatal hypoglycaemia." data-id="CD011967-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 18 Neonatal hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 19 Hyperbilirubinaemia." data-id="CD011967-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 19 Hyperbilirubinaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 20 Admission to NICU." data-id="CD011967-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Oral anti‐diabetic agents versus placebo, Outcome 20 Admission to NICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 1 Hypertensive disorders of pregnancy." data-id="CD011967-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 1 Hypertensive disorders of pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 2 Caesarean section." data-id="CD011967-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 2 Caesarean section.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 3 Perinatal mortality." data-id="CD011967-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 3 Perinatal mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 4 Large‐for‐gestational age." data-id="CD011967-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 4 Large‐for‐gestational age.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 5 Death or serious morbidity composite." data-id="CD011967-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 5 Death or serious morbidity composite. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 6 Use of additional pharmacotherapy." data-id="CD011967-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 6 Use of additional pharmacotherapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 7 Maternal hypoglycaemia." data-id="CD011967-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 7 Maternal hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 8 Glycaemic control (mg/L; mmol/L)." data-id="CD011967-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 8 Glycaemic control (mg/L; mmol/L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 9 Weight gain in pregnancy (Kg)." data-id="CD011967-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 9 Weight gain in pregnancy (Kg).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 10 Induction of labour." data-id="CD011967-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 10 Induction of labour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 11 Perineal trauma." data-id="CD011967-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 11 Perineal trauma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 12 Stillbirth." data-id="CD011967-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 12 Stillbirth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 13 Macrosomia." data-id="CD011967-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 13 Macrosomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 14 Birth trauma." data-id="CD011967-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 14 Birth trauma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 15 Shoulder dystocia." data-id="CD011967-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 15 Shoulder dystocia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 16 Gestational age at birth (weeks)." data-id="CD011967-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 16 Gestational age at birth (weeks).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 17 Preterm birth." data-id="CD011967-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 17 Preterm birth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 18 5‐minute Apgar &lt; 7." data-id="CD011967-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 18 5‐minute Apgar &lt; 7.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 19 Birthweight (g)." data-id="CD011967-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 19 Birthweight (g).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 20 Ponderal index." data-id="CD011967-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 20 Ponderal index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 21 Neonatal hypoglycaemia." data-id="CD011967-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 21 Neonatal hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 22 Respiratory distress syndrome." data-id="CD011967-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 22 Respiratory distress syndrome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 23 Hyperbilirubinaemia." data-id="CD011967-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 23 Hyperbilirubinaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin versus glibenclamide, Outcome 24 Admission to NICU." data-id="CD011967-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Metformin versus glibenclamide, Outcome 24 Admission to NICU.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 1 Caesarean section." data-id="CD011967-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 1 Caesarean section.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 2 Perinatal mortality." data-id="CD011967-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 2 Perinatal mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 3 Large‐for‐gestational age." data-id="CD011967-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 3 Large‐for‐gestational age.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 4 Need for additional pharmacotherapy." data-id="CD011967-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 4 Need for additional pharmacotherapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 5 Maternal hypoglycaemia." data-id="CD011967-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 5 Maternal hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 6 Weight gain in pregnancy (Kg)." data-id="CD011967-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 6 Weight gain in pregnancy (Kg).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 7 Macrosomia." data-id="CD011967-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 7 Macrosomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 8 Small‐for‐gestational age." data-id="CD011967-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 8 Small‐for‐gestational age.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 9 Birth trauma (not specified)." data-id="CD011967-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 9 Birth trauma (not specified).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 10 Gestational age at birth (weeks)." data-id="CD011967-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 10 Gestational age at birth (weeks).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 11 Preterm birth." data-id="CD011967-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 11 Preterm birth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 12 Birthweight (Kg)." data-id="CD011967-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 12 Birthweight (Kg).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 13 Neonatal hypoglycaemia." data-id="CD011967-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 13 Neonatal hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011967-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/urn:x-wiley:14651858:media:CD011967:CD011967-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_t/tCD011967-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glibenclamide versus acarbose, Outcome 14 Respiratory distress syndrome." data-id="CD011967-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Glibenclamide versus acarbose, Outcome 14 Respiratory distress syndrome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/media/CDSR/CD011967/image_n/nCD011967-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes; 24‐30 weeks' gestation; singleton pregnancy. </p> <p><b>Setting</b> : Medical Centre, USA.<br/> <b>Intervention:</b> oral anti‐diabetic pharmacological therapy (glibenclamide)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral anti‐diabetic pharmacological therapies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy ‐ (any type)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/> (135 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.81 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caearean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000<br/> (285 to 483) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.79 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perineal trauma</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000<br/> (0 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98<br/> (0.06 to 15.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>abcd</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Event rates were low 1/189 for anti‐diabetic pharmacological therapy and 1/186 in the control (placebo) group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was not a pre‐specified outcome for the included studies reporting on this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Induction of labour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>222 per 1000<br/> (149 to 331) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.18<br/> (0.79 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ we did not find a published protocol and there were more outcomes reported in the published paper than were listed in the trial registration document ‐ downgraded 1 level.<br/> <sup>b</sup>Generalisability ‐ in this single study 93% of participants were Hispanic women. Results may not be generalisable to other populations ‐ downgraded 1 level.<br/> <sup>c</sup>Imprecision ‐ evidence based on a single study ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ wide confidence intervals crossing the line of no effect and low event rates suggestive of imprecision ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ maternal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants of women diagnosed with gestational diabetes </p> <p>Setting: Medical Centre, USA<br/> <b>Intervention:</b> oral anti‐diabetic pharmacological therapies (glibenclamide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral anti‐diabetic pharmacological therapies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Large‐for‐gestational age</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000<br/> (60 to 187) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.51 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perinatal mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (4 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.97<br/> (0.36 to 10.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>abcd</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Event rates were low with 4/189 for oral anti‐diabetic pharmacological therapy and 2/186 for placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity (neonate, child, adult) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes (child, adult) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies pre‐specified this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ we did not find a published protocol and there were more outcomes reported in the published paper than were listed in the trial registration document ‐ downgraded 1 level.<br/> <sup>b</sup>This single trial comprised 93% Hispanic women. The results may not be generalisable ‐ downgraded 1 level.<br/> <sup>c</sup>Imprecision ‐ evidence was based on a single trial only ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecison ‐ wide confidence intervals crossing the line of no effect and low event rates ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral anti‐diabetic pharmacological therapies versus placebo ‐ neonatal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin versus glibenclamide ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin versus glibenclamide ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes </p> <p><b>Setting:</b> trials conducted in Brazil, India and the USA<br/> <b>Intervention:</b> metformin<br/> <b>Comparison:</b> glibenclamide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (33 to 114) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.38 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/> (325 to 674) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20<br/> (0.83 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>bc</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had pre‐specified development of type 2 diabetes as an outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perineal trauma</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (1 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67<br/> (0.22 to 12.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ad</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note low event rates (2/154 for metformin and 1/154 for glibenclamide</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had return to pre‐pregnancy weight as a pre‐specified outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies for this comparison had postnatal depression as a pre‐specified outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induction of labour</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>496 per 1000<br/> (374 to 655) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.61 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ae</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ all studies were open label ‐ downgraded 1 level.<br/> <sup>b</sup>Risk of bias ‐ 3 of the 4 studies were open label and 3 of 4 studies were unclear for blinding of outcome assessors. 2 studies reported additional outcomes that were not pre‐specified ‐ downgraded 1 level.<br/> <sup>c</sup>Inconsistency ‐ heterogeneity was high, I<sup>2</sup> = 61% downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ wide confidence intervals along with low event rates suggest imprecision ‐ downgraded 1 level.<br/> <sup>e</sup>Imprecision ‐ evidence was based on a single trial ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin versus glibenclamide ‐ maternal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin versus glibenclamide ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin versus glibenclamide ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Infants of women diagnosed with gestational diabetes </p> <p><b>Setting:</b> trials conducted in Brazil, India and the USA<br/> <b>Intervention:</b> metformin<br/> <b>Comparison:</b> glibenclamide </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>193 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>129 per 1000<br/> (46 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67<br/> (0.24 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>246<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.06 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note that event rates were very low. 1 study had no event of perinatal death in either the metformin nor the glibenclamide group. The second study had 1 death in each group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (109 to 329) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.54<br/> (0.31 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (20 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.42 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ae</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified adiposity as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified diabetes as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials for this comparison had pre‐specified neurosensory disability as a trial outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ allocation concealment was unclear in 1 study. 1 study was open label ‐ downgraded 1 level.<br/> <sup>b</sup>Inconsistency ‐ heterogeneity was I<sup>2</sup>= 54%, which could not be explained by the diagnostic criteria used ‐ downgraded 1 level.<br/> <sup>c</sup>Risk of bias ‐ includes open label study/studies with no evidence of blinding of participants or researchers ‐ downgraded 1 level.<br/> <sup>d</sup>Imprecision ‐ evidence based on a single small study ‐ downgraded 1 level.<br/> <sup>e</sup>Imprecision ‐ event rates low (&lt; 30) ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Metformin versus glibenclamide ‐ neonatal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glibenclamide versus acarbose ‐ maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Glibenclamide versus acarbose ‐ maternal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women diagnosed with gestational diabetes; 11 to 33 weeks' gestation; singleton pregnancy </p> <p><b>Setting:</b> Maternity hospital, Brazil<br/> <b>Intervention:</b> Glibenclamide<br/> <b>Comparison:</b> Acarbose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acarbose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other oral anti‐diabetic agent</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertensive disorders of pregnancy ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caesarean section</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>526 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/> (279 to 895) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.53 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perineal trauma ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to pre‐pregnancy weight ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postnatal depression ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induction of labour ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Method of randomisation was unclear and the study was open‐label ‐ downgraded ‐1 level.<br/> <sup>b</sup>Evidence based on a single small study ‐ downgraded ‐1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Glibenclamide versus acarbose ‐ maternal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011967-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glibenclamide versus acarbose ‐ neonatal outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Glibenclamide versus acarbose ‐ neonatal outcomes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gestational diabetes </p> <p><b>Setting:</b> maternity hospital, Brazil<br/> <b>Intervention:</b> glibenclamide<br/> <b>Comparison:</b> acarbose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with acarbose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with glibenclamide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>251 per 1000<br/> (57 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.38<br/> (0.54 to 10.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perinatal mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events were reported in either group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death or serious morbidity composite ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53/1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333/1000</p> <p>(46 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.33 (0.87 to 46.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>ab</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low event rates and sample size (8/24 in glibenclamide group and 1/19 in acarbose group) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adiposity ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diabetes ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurosensory disability in later childhood ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias ‐ evidence of selective reporting ‐ downgraded 1 level.<br/> <sup>b</sup>Imprecision ‐ evidence based on a single small study with wide confidence intervals ‐ downgraded 1 level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glibenclamide versus acarbose ‐ neonatal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Examples of diagnostic criteria for gestational diabetes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Organisation/professional body</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Screening and diagnostic criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1‐hour oral glucose challenge test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oral glucose tolerance tes</b>t </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fasting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1 hour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2 hour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 hour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0021" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2013;36(Suppl 1):567‐74. ">ADA 2013</a><sup>a</sup>, <a href="./references#CD011967-bbs2-0061" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel, MetzgerBE , GabbeSG , PerssonB , BuchananTA , CatalanoPA , DammP , et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676‐82. ">IADPSG 2010</a><sup>a</sup>, ADIPS 2013 (<a href="./references#CD011967-bbs2-0080" title="NankervisA , McIntyreHD , MosesR , RossGP , CallawayL , PorterC , et al. ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf(accessed 2014). ">Nankervis 2014</a>)<sup>a</sup>, <a href="./references#CD011967-bbs2-0103" title="World Health Organization. WHO Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Report WHO/NMH/MND/13.2. Geneva, Switzerland: WHO, 2014. ">WHO 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.1 mmol/L</p> <p>(≥ 92 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10 mmol/L</p> <p>(≥ 180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.5 mmol/L</p> <p>(≥ 153 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD011967-bbs2-0020" title="American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician‐gynecologists. Obstetrics &amp; Gynecology2013;122(2 Pt 1):406‐16. ">ACOG 2013</a> </p> <p>Carpenter and Coustan<sup>b</sup> </p> <p>National Diabetes Data Group<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>(&gt; 7.2 mmol/L;</p> <p>&gt; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.3 mmol/L</p> <p>(≥ 95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10 mmol/L</p> <p>(≥180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.6 mmol/L</p> <p>(≥ 155 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.8 mmol/L</p> <p>(≥ 140 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>(&gt; 7.8 mmol/L; &gt; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.8 mmol/L</p> <p>(≥ 105 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10.6 mmol/L</p> <p>(≥ 190 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.2 mmol/L</p> <p>(≥ 165 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 8.0 mmol/L</p> <p>(≥ 145 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0032" title="Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes2013;37 (Suppl 1):S1‐S212. ">Canadian Diabetes Association 2013</a> </p> <p>either<sup>a</sup> </p> <p>or<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g</p> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.3 mmol/L</p> <p>(≥ 95 mg/dL)</p> <p>≥ 5.1 mmol/L</p> <p>(≥ 92 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10.6 mmol/L</p> <p>(≥ 190 mg/dL)</p> <p>≥ 10 mmol/L</p> <p>(≥ 180 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.0 mmol/L</p> <p>≥ 8.5 mmol/L</p> <p>(≥ 153 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0082" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline NG3. London: NICE, 2015. ">NICE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.6 mmol/L</p> <p>(≥ 101 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.8 mmol/L</p> <p>(≥ 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0081" title="National Institute for Health and Clinical Excellence (NICE). Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre‐conception to the Postnatal Period. NICE clinical guideline 63. London: NICE, 2008. ">NICE 2008</a>; <a href="./references#CD011967-bbs2-0102" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Geneva, Switzerland: WHO, 1999. ">WHO 1999</a>; <a href="./references#CD011967-bbs2-0060" title="HoffmanL , NolanC , WilsonJD , OatsJJ , Simmons D. The Australasian Diabetes in Pregnancy Society. Gestational diabetes mellitus‐management guidelines. Medical Journal of Australia1998;169(2):93‐7. ">Hoffman 1998</a> (ADIPS)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 7.0 mmol/L</p> <p>(≥ 126 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 11.1 mmol/L</p> <p>(≥ 200 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New Zealand <a href="./references#CD011967-bbs2-0076" title="Ministry of Health. Screening, Diagnosis and Management of Gestational Diabetes in New Zealand: A Clinical Practice Guideline. Wellington: Ministry of Health, 2014. ">Ministry of Health 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 g if HbA1c &lt; 41 mmol/mol</p> <p>(≥ 7.8 mmol/L; ≥ 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 5.5 mmol/L</p> <p>(≥ 99 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 9.0 mmol/L</p> <p>(≥ 162 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ADA: American Diabetes Association<br/> IADPSG: International Association of the Diabetes and Pregnancy Study Groups<br/> ADIPS: Australasian Diabetes in Pregnancy Society<br/> ACOG: American College of Obstetrics and Gynecology<br/> NICE: National Institute for Health and Care Excellence<br/> <sup>a</sup>1 abnormal result required for diagnosis<br/> <sup>b</sup>2 or more abnormal results required for diagnosis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Examples of diagnostic criteria for gestational diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean maternal age (years) ± SD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 4.5 (n = 24), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5 ± 5.8 (n = 19), acarbose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3 ± 6, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 6, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.4 ± 4.4 (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.6 ± 4.6 (n = 80), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 ± 7.1 (n = 75) ‐ metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.6 ± 7.8 (n = 74), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, standard care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated, glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlopropramide 30.9 (n = 58)</p> <p>Tolbutamide 29.7 (n = 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diet 32.7 (n = 56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6 ± 5.6 (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3 ± 5.4 (n = 96), glibenclamide</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean maternal age (years) ± SD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Maternal BMI kg/m2 </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Timepoint BMI measured at</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.5 ± 5.8 (n = 24), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.7 ± 4.2 (n = 19), acarbose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.0 ± 4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.9 ± 5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐pregnancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 4.4 (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.8 ± 4.0 (n = 80), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.8 ± 5.8 (n = 75), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.7 ± 7.0 (n = 74), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.7 ± 5.4 (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 ± 5.9 (n = 96), glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Maternal BMI kg/m2 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Gestational age at trial entry</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.0 ± 2.0, glibenclamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.0 ± 1.0, placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.3 ± 3.3 weeks' (n = 79), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.7 ± 3.7 weeks' (n = 80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3 ± 6.8 weeks' (n = 75), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.1 ± 5.0 weeks' (n = 74), glibenclamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.0 ± 6.4 weeks' (n = 104), metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.4 ± 7.1 weeks' (n = 96), glibenclamide</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Gestational age at trial entry</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnostic criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Timing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Screening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diagnosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐28 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour, 50 g OGCT(≥ 7.8 mmol/L; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>3 hour, 100 g OGTT</p> <p>Fasting &lt; 5.8 mmol/L (105 mg/dL)</p> <p>1‐hour ≥ 10.6 mmol/L (190 mg/dL)</p> <p>2‐hour ≥ 9.2 mmol/L (165 mg/dL)</p> <p>3‐hour ≥ 8.1 mmol/L (145 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Diabetes Data Group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 g OGTT</p> <p>Fasting ≥ 6.1 mmol/L (110 mg/dL);</p> <p>2‐hour value ≥ 7.8 mmol/L (140 mg/dL).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria (old)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐34 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria but not stated if 1999 or 2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.8 mmol/L; 140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>100 g OGTT:</p> <p>fasting glucose ≥ 5.3 mmol/L,</p> <p>1‐hour ≥ 10 mmol/L,</p> <p>2‐hour ≥ 8.6 mmol/L,</p> <p>3‐hour ≥ 7.8 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24‐28 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal values</p> <p>100 g OGTT:</p> <p>fasting glucose ≥ 5.3 mmol/L,</p> <p>1‐hour ≥ 10 mmol/L,</p> <p>2‐hour ≥ 8.6 mmol/L,</p> <p>3‐hour ≥ 7.8 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>National Diabetes Data Group (1979)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.2 mmol/L; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hour 100 g OGTT using criteria with 2 or more abnormal results.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fasting blood glucose 5.1 to 5.4 mmol/L,</p> <p>2 hour &lt; 8.5 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11‐33 weeks'</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hour 50 g OGCT (≥ 7.2 mmol/L; 130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 hour 100 g OGTT using criteria with 2 or more abnormal results.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carpenter and Coustan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO criteria (1999)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>OGCT oral glucose tolerance test; OGTT oral glucose tolerance test</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnostic criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011967-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Treatment target</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fasting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1‐hour post‐prandial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2‐hour post‐prandial</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0002" title="Abbassi‐GhanavatiM , CaeyB , ShivversS , TudelaC , McIntireD , LevenoK . Randomized trial of glyburide plus diet compared with placebo plus diet in women with gestational diabetes. American Journal of Obstetrics and Gynecology2014;210:S179. CaseyB , DuryeaEL , Abbassi‐GhanavatiM , TudelaCM , ShivversSA , McIntireDD , et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2015;126(2):303‐9. ">Casey 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0001" title="BertiniAM , SilvaJC , TabordaW , BeckerF , BebberFRL , ViesiJMZ , et al. Perinatal outcomes and the use of oral hypoglycaemic agents. Journal of Perinatal Medicine2005;33:519‐23. SilvaJC , TabordaW , BeckerF , AquimG , VieseJ , BertiniAM . Preliminary results of the use of oral hypoglycemic drugs on gestational diabetes mellitus [Resultados preliminares do uso de anti‐hiperglicemiantes orais no diabete melito gestacional]. Revista Brasileira de Ginecologia y Obstetricia2005;27(8):461‐6. ">Bertini 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.0 mmol/L</p> <p>(90 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.5 mmol/L</p> <p>(100 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0003" title="CortezJ , TarsaM , AgentS , ChmaitR , MooreT . Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S149. ">Cortez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7.5 mmol/L</p> <p>(135 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0004" title="DeBaccoG , GenroV , SalazerC , OppermanM . High rate of hypoglycemia in diabetic pregnant women on use of glyburide. Diabetology &amp; Metabolic Syndrome2015;7(Suppl 1):A85. OppermannMLR . Oral antidiabetic agents in pregnancy [Oral antidiabetic agents on gestational diabetes: Modulating effect on fetal growth ‐ a clinical randomized trial]. clinicaltrials.gov/show/NCT02091336 Date first received: 25 February 2014. ">De Bacco 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0005" title="FennMG , IsacM , GeorgeM , KorulaS . Comparison of metformin with glyburide in gestational diabetes: a double blind randomised clinical trial. Journal of Evolution of Medical and Dental Sciences2015;4(28):4803‐8. ">Fenn 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7.8 mmol/L</p> <p>(140 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0006" title="CTRI/2014/02/004418 . Metformin vs glyburide in gestational diabetes ‐ a randomised controlled trial. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8029 Date first received: 18 February 2014. GeorgeA , MathewsJE , SamD , BeckM , Benjamin , SJ , AbrahamA , et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide ‐ a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2015;55:47‐52. ">George 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0007" title="MooreL , ClokeyD , CuretL . A randomized controlled trial of metformin and glyburide in gestational diabetes. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S34. MooreL , ClokeyD , RobinsonA . A randomized trial of metformin compared to glyburide in the treatment of gestational diabetes. American Journal of Obstetrics and Gynecology2005;193(6 Suppl):S92. MooreLE , ClokeyD , RappaportVJ , CuretLB . Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstetrics &amp; Gynecology2010;115(1):55‐9. ">Moore 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 5.8 mmol/L</p> <p>(105 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0008" title="EUCTR:2013‐004065‐13 . Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study. clinicaltrialsregister.eu/ctr‐search/trial/2013‐004065‐13/GB Date first received: 23 October 2013. ISRCTN86503951 . Management of mild gestational diabetes mellitus (GDM). isrctn.com/ISRCTN86503951 Date first received: 8 January 2014. ">Myers 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0009" title="NachumZ , ZafranN , SalimR , HissinN , HasaneinJ , LetovaYGZ , et al. A comparison between two oral hypoglycemics: glyburide and metformin and their combination for the treatment of gestational diabetes mellitus ‐ a prospective randomized controlled trial. American Journal of Obstetrics and Gynecology2015;212(1 Suppl 1):S23. ">Nachum 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 5.3 mmol/L</p> <p>(95 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 minutes</p> <p>&lt; 7.2 mmol/L</p> <p>(130 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0010" title="NotelovitzM . Sulphonylurea therapy in the treatment of the pregnant diabetic. South African Medical Journal1971;45:226‐9. ">Notelovitz 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3 mmol/L*</p> <p>(150 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011967-bbs2-0011" title="BertiniAM . Up to date treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2009;37(Suppl 1):3. SilvaJC , FachinDRRN , CoralML , BertiniAM . Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. Journal of Perinatal Medicine2012;40(3):225‐8. SilvaJC , PachecoC , BizatoJ , deSouzaBV , RibeiroTE , BertiniAM . Metformin compared with glyburide for the management of gestational diabetes. International Journal of Gynecology &amp; Obstetrics2010;111(1):37‐40. ">Silva 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.0 mmol/L</p> <p>(90 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6.7 mmol/L</p> <p>(120 mg/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Post‐prandial timing not specified</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Treatment target</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/full#CD011967-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011967-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral anti‐diabetic agents versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hypertensive disorders of pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hypertensive disorders of pregnancy (any type)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.81, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pregnancy‐induced hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.71, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pre‐eclampsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.59, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Large‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Use of additional pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.42, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.42, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Glycaemic control (end of treatment) (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐5.13, ‐0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Weight gain in pregnancy (Kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.96, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Induction of labour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.79, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Perineal trauma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.58, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Macrosomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Birthweight (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.0 [‐134.53, 68.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Shoulder dystocia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Bone fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.17, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Nerve palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.32, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Neonatal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.36, 10.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Hyperbilirubinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.50, 7.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.53, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral anti‐diabetic agents versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011967-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin versus glibenclamide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hypertensive disorders of pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pre‐eclampsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pregnancy‐induced hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.37, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.83, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Carpenter and Coustan criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.53, 10.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 National Diabetes Data Group criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.75, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 World Health Organization (1999)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Perinatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.06, 14.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Large‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.24, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Carpenter and Coustan criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.38, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 World Health Organization (1999)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.21, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Death or serious morbidity composite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.31, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Use of additional pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.28, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.36, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Glycaemic control (mg/L; mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Fasting blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Postprandial blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.01, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 HbA1c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.39, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Weight gain in pregnancy (Kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.06 [‐3.98, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Induction of labour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Perineal trauma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.22, 12.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.06, 14.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Macrosomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.23, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Birth trauma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Shoulder dystocia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 6.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.22, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.59, 4.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 5‐minute Apgar &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Birthweight (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐209.13 [‐314.53, ‐103.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Ponderal index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.17, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Neonatal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.42, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Hyperbilirubinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.37, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.65, 3.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin versus glibenclamide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011967-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Glibenclamide versus acarbose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.53, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Perinatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Large‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.54, 10.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for additional pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.19, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Maternal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Weight gain in pregnancy (Kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.13, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Macrosomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.20 [0.41, 125.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Small‐for‐gestational age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Birth trauma (not specified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.82, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Preterm birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Birthweight (Kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>153.0 [‐123.52, 429.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Neonatal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.33 [0.87, 46.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Glibenclamide versus acarbose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011967.pub2/references#CD011967-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011967.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011967-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011967-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011967-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011967-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011967-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011967-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011967-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011967-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011967\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011967\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011967\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011967\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011967.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011967.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011967.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720096815"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011967.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720096819"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011967.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df8d54c8d9377',t:'MTc0MDcyMDA5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 